document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences truvada viread hepsera ambisome emtriva complera eviplera vistide letairis volibris ranexa cayston rapiscan atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiestable content annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption table content item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hivaid liver disease hepatitis cardiovascularmetabolic respiratory condition headquarter foster city california operations north america europe asia pacific continue seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy past year execute philosophy strategy bring bestinclass drug market keeping strategy complete acquisition licensing transaction enhance pipeline expand singletablet regimen product offering treatment hiv launch compleraeviplera emtricitabinerilpivirinetenofovir disoproxil fumarate anticipate launch quad combine hiv medicine oncedaily singletablet regiman pende food drug administration fda approval large transaction acquisition pharmasset inc january billion year focus large proportion research development effort discover advance directacting antiviral treatment chronic hepatitis virus hcv hcv therapeutic market continue vastly underserve limitation available therapy small fraction individual infect hcv diagnose small fraction patient treat prior protease inhibitor approve half patient respond standard care combination pegylate interferon ribavirin addition protease inhibitor standard care result incremental response rate patient genotype infection regimen cause substantial effect fatigue bone marrow suppression potentially debilitate rash anemia neuropsychiatric effect discontinuation rate triple therapy combination significantly increase year progress early stage hcv molecule mechanism action clinical development field hcv research evolve rapidly clear hcv portfolio oral antiviral development compound difficulty compete development program competitor acquisition pharmasset gain ownership advanced date potent nucleotide analog act inhibit replication hcv limited safety resistance concern detect far compound study extensively phase study genotype infect patient combination ribavirin pegylate interferon currently study genotype infect patient phase trial know fission evaluate genotype patient currently enrol second phase study genotype patient schedule begin enrol week phase datum genotype patient consistent datum phase trial expect file new drug application nda treatment genotype patient potential approval late early third hcvinfecte individuals united states europe infect hcv genotype conducting phase study determine efficacy plus ribavirin population result study available month expect datum evaluate plus ribavirin week genotype treatmentnave patient arm quantum study patient available end quarter expect follow second quarter datum arm electron study involve treatmentnave patient treat week early quarter datum ribavirin treatment week arm quantum study available table content february announce majority hcv genotype patient prior null response interferoncontaine regiman enrol arm ongoing electron study experience viral relapse week complete week treatment plus ribavirin patient randomize arm electron study datum available patient time announcement patient experience viral relapse patient relapse reach week posttreatment time point datum indicate treatment genotype patient classify null responder plus ribavirin week sufficient cure disease regulatory authority require patient sustain viral response week cessation therapy consider cure disease extent datum electron quantum study indicate genotype treatmentnave patient effectively treat ribavirin large phase study genotype patient expect commence able commence phase trial timeline result trial positive expect file nda include datum genotype patient potential approval ribavirin sufficiently effective treat genotype treatmentnave patient need explore combination therapy direct act antiviral compound portfolio delay development approval use genotype treatmentnave patient expect begin clinical study evaluate combination nsa inhibitor genotype treatmentnave patient second quarter risk factor entitle public announcement datum clinical study evaluate hcvinfecte patient likely cause significant volatility stock price product hivaid atripla efavirenz emtricitabine tenofovir disoproxil fumarate oral formulation dose day treatment hiv infection adult atripla oncedaily singletablet regimen hiv intend stand therapy combination antiretroviral fixeddose combination antiretroviral medication viread tenofovir disoproxil fumarate emtriva emtricitabine bristol myerssquibb company bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old viread approve treatment chronic hepatitis adult compleraeviplera oral formulation dose day treatment hiv infection treatmentnave adult product market united states complera europe eviplera second complete singletablet regimen treatment hiv fixeddose combination antiretroviral medication viread emtriva tibotec pharmaceutical nonnucleoside reverse transcriptase inhibitor edurant rilpivirine emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child liver disease viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment chronic hepatitis adult compensate decompensate liver disease table content license glaxosmithkline inc gsk right commercialize viread treatment chronic hepatitis asia certain territory note viread approve treatment hiv infection patient year age old combination antiretroviral agent hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat chronic hepatitis patient year age old license gsk right commercialize hepsera treatment chronic hepatitis asia latin america certain territory cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg rights ranexa territory outside united states lexiscanrapiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc exclusive right manufacture sell regadenoson lexiscan united states subject obligation pay royalty base sale lexiscan united states rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory respiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis patient year age old pseudomona aeruginosa aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin liposome injection proprietary liposomal formulation amphotericin antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patient aid macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen table content develop eyetech inc eyetech technology license promote united states eyetech eyetech hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty eyetech base sale macugen worldwide follow table list aggregate product sale major product thousand total total total product product product sale sale sale antiviral product atripla truvada viread hepsera compleraeviplera emtriva total antiviral product ambisome letairis ranexa total product sale item note consolidated financial statement include annual report total revenue geographic area commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium canada denmark finland france germany greece hong kong ireland italy netherlands new zealand norway poland portugal south korea spain sweden switzerland turkey united kingdom united states product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute atripla truvada viread hepsera complera emtriva ranexa vistide united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute atripla truvada viread hepsera emtriva compleraeviplera ambisome asia australia canada europe latin america middle east new zealand commercial team thirdparty distributor corporate partner table content rely corporate partner help promote sell product collaboration agreement example bms right promote atripla united states bms right promote atripla majority country europe limited number central eastern european country gilead bms thirdparty distributor sole promote sell distribute company agreement merck inc merck promote distribute atripla country latin america asia pacific merck exist thirdparty distributor license gsk right promote sell viread hepsera treatment hepatitis certain country outside united states license right manufacture sell tamiflu macugen lexiscanrapiscan worldwide party subject corporate partner obligation pay royalty base percentage sale product access develop world gilead access program establish certain hiv product available substantially reduce price country develop world develop system tiere pricing reflect economic status gross national income capita gni hiv prevalence approach allow price therapy base country ability pay support clinical study donation product help define good treatment strategy develop world country example donate tenofovir centre aids programme research south africa caprisa microbicide trial assess effectiveness safety tenofovirbase microbicide gel prevention hiv infection south african woman provide drug number innovative international study investigate viread truvada prevent hiv transmission atrisk uninfected adult potential hiv prevention strategy call preexposure prophylaxis prep december announce submission supplemental nda snda fda approval oncedaily truvada prep reduce risk hiv infection uninfected adult snda approve truvada agent indicate uninfected individual reduce risk acquire hiv sex work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire support clinical research study aim identify good treatment course visceral leishmaniasis donate ambisome support clinical study assess combination therapy costeffectiveness multiple visceral leishmaniasis treatment intervention december sign partnership agreement world health organization donate vial ambisome year donation treat patient resourcelimite country enter number collaboration relate access product develop world include pharmachem technologies grand bahama ltd pharmachem pharmachem commercial manufacturing partner establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient atripla truvada resource limited country cooperative effort pharmachem grand bahama port authority partnership increase manufacturing capacity hiv medicine improve delivery efficiency medicine produce near market need aspen pharmacare holding ltd aspen enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada treatment hiv infection certain develop world country include gilead access program amend agreement aspen amend table content agreement aspen retain right manufacture distribute viread truvada treatment hiv infection develop world country aspen right purchase viread truvada unlabeled bottle distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale viread truvada royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination generic version emtricitabine manufacture distribute aspen license generic manufacturer enter nonexclusive license agreement thirteen indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india low income country gilead access program agreement require generic manufacturer meet certain national international regulatory standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product expand nonexclusive license agreement increase number country include license include right future pipeline product elvitegravir investigational integrase inhibitor cobicistat investigational antiretroviral boost agent quad combine hiv medicine oncedaily singletablet regiman pende fda approval expand access viread treatment hepatitis treatment develop country include nonexclusive license agreement ability manufacture distribute generic version tenofovir disoproxil fumarate treatment hepatitis country authorize sell generic version tenofovir disoproxil fumarate hiv merck enter agreement affiliate merck pursuant gilead merck provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement international partnership microbicide ipm conrad enter agreement grant right ipm conrad cooperate agency agency international development commit improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country certain formulation tenofovir use topical microbicide prevent hiv infection medicine patent pool pool enter agreement pool organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant pool nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee pool free develop combination product pediatric formulation hiv medicine grant pool right grant sublicense future pipeline product elvitegravir cobicistat quad generic pharmaceutical manufacturer india distribution develop world tibotec pharmaceutical tibotec expand agreement tibotec provide distribution compleraeviplera treatment hiv develop country enable commercialization generic version product table content competition product target number area include viral cardiovascular respiratory fungal disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell joint venture viiv establish november gsk pfizer focus hiv therapie hiv product compete broadly hiv product abbott laboratories inc boehringer ingelheim gmbh merck roche tibotec bmss videx didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine bmss zerit stavudine face generic competition united states result launch generic stavudine lamivudine market viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal recently receive pricing approval italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey date significant impact generic didanosine zidovudine stavudine lamivudine generic version combivir generic tenofovir turkey price hiv product price decrease hiv product result long term liver disease product hepatitis virus hbv product viread hepsera face significant competition exist expect therapy treat patient chronic hepatitis erode revenue receive sale hbv product hbv product face competition baraclude entecavir oral nucleoside table content analog develop bms launch united states tyzekasebivo telbivudine oral nucleoside analog develop novartis pharmaceutical corporation novartis sale united states european union china hbv product compete epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia viread hepsera treatment chronic hepatitis compete establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment chronic hepatitis cardiovascular product letairis compete directly tracleer bosentan sell actelion pharmaceutical inc actelion indirectly pah product united therapeutics corporation ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscanrapiscan clinical data inc develop apadenoson pharmacologic stress agent mpi currently phase clinical trial stress agent product candidate compete lexiscanrapiscan respiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication sell novartis treatment patient lung contain aeruginosa tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trial product ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin product include abelcet amphotericin lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin liposomal sell genpharma argentina bms numerous generic manufacturer sell conventional amphotericin compete ambisome table content aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association vistide compete number drug treat cytomegalovirus retinitis include cytovene cytovene ganciclovir sell intravenous oral formulation respectively roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc united states novartis territory outside united states number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business find item note consolidated financial statement include annual report commercial collaboration currently number collaboration corporate partner govern manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist roche enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale agreement receive upfront payment million entitle receive additional milestone payment million achievement certain development regulatory objective receive milestone payment roche cash payment million relate reimbursement certain research preclinical development expense obligation prosecute maintain certain patent agreement enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment table content provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative roche amendment option provide specialized sale force supplement roche marketing effort tamiflu exercise date agreement roche obligation pay royalty terminate countrybycountry basis patent provide exclusivity tamiflu country expire roche terminate agreement reason case right tamiflu revert party terminate agreement response material breach party bm enter collaboration bms develop commercialize singletablet regimen truvada bmss sustiva united states combination approve use united states sell brand atripla bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royalty free sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada sustiva respectively net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort level agree annually bms gilead second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party begin reduce joint promotional effort canada launch complera anticipation launch quad party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern primary joint committee form bms gilead responsible accounting financial reporting tax reporting product distribution joint venture bms amend joint venture collaboration agreement allow joint venture sell atripla canada agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product nonterminate party right continue sell atripla obligate pay terminate party certain royalty threeyear period follow effective date termination enter collaboration agreement bms set forth term condition bms commercialize atripla european union iceland liechtenstein norway switzerland bms thirdparty distributor act sell party country responsible thing receive process customer order warehouse product collect receivables handling return manufacture atripla coordinate primarily responsible distribution logistic general party share revenue outofpocket expense proportion net selling price truvada respect efavirenz respect bms start limited number activity jointly manage party long coordinate detail promotional activity region agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european country cover agreement prior time party terminate agreement reason termination effective december nonterminate party right continue table content sell atripla obligate pay terminate party certain royalty threeyear period follow effective date termination event nonterminate party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early gsk sublicense gsk exclusive right market ambrisentan active pharmaceutical ingredient letairis volibris pah territory outside united states license agreement receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million december receive million potential milestone payment addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development agreement gsk obligation pay royalty terminate countrybycountry basis early date generic equivalent sell country achieve certain percentage total prescription product plus generic equivalent fifteenth anniversary commercial launch country gsk terminate agreement reason termination right product revert party terminate agreement response material breach party tibotec enter collaboration agreement tibotec develop commercialize fixeddose combination truvada tibotecs rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement tibotec grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan party restrict combine drug drug december record million approximately million reimbursable expense incur tibotec development rilpivirine maximum reimbursable term agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product license country tibotec exercise right codetail combination product country gilead sell party price product expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase tibotec compleraeviplera approximate market price rilpivirine specified percentage thirty percent july amend collaboration agreement include distribution compleraeviplera rest world distribute product north america europe latin america australia new zealand tibotec distribute product region include japan russia party terminate collaboration agreement compleraeviplera withdraw market party materially breach agreement terminate agreement united states canada expiration expire patent tenofovir disoproxil fumarate united states terminate agreement country expiration expire patent tenofovir disoproxil fumarate country european union tibotec terminate agreement united states canada expiration table content expire patent rilpivirine united states terminate agreement country expiration expire patent rilpivirine country european union research collaboration currently number collaboration corporate partner govern research development certain compound drug candidate research collaboration japan tobacco inc japan tobacco collaboration significant financial statement perspective significant ongoing collaboration activity exist japan tobacco enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv infection bear cost expense associate commercialization effort term agreement pay upfront license fee million obligate total potential milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale territory market product december total milestone payment million agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research development research development philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need apply expertise drug discovery development target specific medical need new well treatment need intend continue commit significant resource research development opportunitie business development activity product development effort cover wide range medical condition include hivaid liver disease hepatitis cardiovascularmetabolic respiratory inflammationoncology disease research scientist foster city palo alto san dimas oceanside california branford connecticut princeton new jersey seattle washington engage discovery development new molecule technology hope lead new medicine novel formulation exist drug development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process table content summary key product candidate correspond current stage development additional information development pipeline visit website wwwgileadcom product candidate treatment hiv product candidate description marketing application pende integrase october submit new drug application nda food drug administration fda singletablet marketing approval oncedaily singletablet quad regimen elvitegravir cobicistat tenofovir regimen quad disoproxil fumarate emtricitabine december fda accept nda review set target review date august addition fda indicate panel convene timeframe provide expert advice application december announce submit marketing authorization application european medicine agency marketing approval singletablet regimen phase cobicistat cobicistat pharmacoenhancer evaluation boost agent certain hiv medicine treatmentnave patient base positive clinical trial result expect submit nda product second quarter elvitegravir elvitegravir oral integrase inhibitor evaluate combination therapy hiv treatmentexperience patient base positive clinical trial result expect submit nda product second quarter phase nucleotide reverse transcriptase inhibitor evaluate treatment hivaid product candidate treatment liver disease product candidate description phase nucleotide nsb inhibitor evaluation treatment hcv currently enrol genotype patient phase clinical program ribavirin evaluate combination ribavirin genotype treatmentnave null responder patient null responder patient respond early interferonbase therapy february announce majority hcv genotype patient prior null response interferoncontaine regiman enrol arm ongoing electron study experience viral relapse week complete week treatment plus ribavirin patient randomize arm electron study datum available patient time announcement patient experience viral relapse patient relapse reach week post treatment time point datum genotype null responder table content product candidate description arm study present upcoming scientific conference datum indicate treatment genotype patient classify null responder plus ribavirin week sufficient cure disease expect receive datum ongoing study treatmentnave patient ribavirin month describe overview item business phase oral nsa inhibitor evaluation treatment hepatitis oral protease inhibitor evaluate treatment hepatitis oral protease inhibitor evaluate treatment hepatitis clinical trial plan time product candidate description tegobuvir tegobuvir oral nsb nonnucleoside polymerase inhibitor evaluate treatment hepatitis monoclonal antibody evaluate treatment liver fibrosis phase nucleoside reverse transcriptase inhibitor evaluation treatment hepatitis oral tlr agonist treatment hepatitis hepatitis nonnucleoside polymerase inhibitor evaluation treatment hepatitis clinical trial plan time product candidate treatment cardiovascularmetabolic disease product candidate description phase ranolazine ranolazine late sodium current inhibitor approve treatment chronic angina evaluate treatment incomplete revascularization postpercutaneous coronary intervention treatment type diabetes expect complete phase trial evaluate ranolazine treatment incomplete revascularization postpercutaneous coronary intervention half phase trial evaluate ranolazine treatment treatment type diabetes second half table content product candidate treatment respiratory disease product candidate description phase aztreonam inhalation solution aztreonam inhalation solution evaluate treatment bronchiectasis expect complete enrollment phase trial early phase monoclonal antibody evaluate treatment idiopathic pulmonary fibrosis product candidate treatment inflammationoncology disease product candidate description phase pik delta inhibitor antibody evaluate treatment chronic lymphocytic leukemia expect complete enrollment phase trial treatment chronic lymphocytic leukemia half phase pik delta inhibitor antibody evaluate treatment indolent nonhodgkin lymphoma monoclonal antibody evaluate treatment myelofibrosis colorectal cancer pancreatic cancer phase syk inhibitor evaluate treatment rheumatoid arthritis total expense billion compare billion million addition internal discovery clinical development program seek add portfolio product product acquisition collaboration follow table show recent acquisition year company therapeutic area therapeutics inc cardiovascular disorder cgi pharmaceuticals inc inflammatory disease arresto biosciences inc fibrotic disease cancer calistoga pharmaceuticals inc cancer inflammatory disease pharmasset inc chronic hepatitis virus large transaction acquisition pharmasset inc january billion pharmasset clinicalstage pharmaceutical company locate princeton new jersey commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection acquisition pharmasset gain ownership advanced date potent nucleotide analog act inhibit replication hcv limited safety resistance concern detect far risk factor entitle public announcement datum clinical study evaluate hcvinfecte patient likely cause significant volatility stock price table content patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date united states europe primary patent patent issue pende application phase product candidate phase product candidate patent expiration product candidate treatment hiv cobicistat elvitegravir integrase singletablet regimen quad product candidate treatment liver disease product candidate treatment respiratory disease aztreonam inhalation solution treatment bronchiectasis product candidate treatment cardiovascularmetabolic disease ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type diabetes reflect possible patent term restoration future supplementary protection certificate depend circumstance surround regulatory approval product patent relevance product finally approve application pende base patent expiration date elvitegravir component quad follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product european patent patent product expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread ranexa lexiscan emtriva truvada atripla cayston compleraeviplera supplementary protection certificate spc protection obtain certain european country confer auxiliary form patent exclusivity indicate table content pediatric exclusivity grant extend patent expiration pediatric exclusivity grant extend patent expiration base patent expiration date viread component truvada base patent expiration date viread component atripla base patent expiration date edurant component compleraeviplera patent protection certain challenge patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy patent cover active pharmaceutical ingredient atripla truvada viread emtriva compleraeviplera hepsera letairis vistide lexiscan hold party acquire exclusive right patent agreement party patent cover ranolazine active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapy hepatitis indication hepsera develop obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license alternative technology unable develop commercialize product business adversely affect example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis addition patent claim chemical entity metabolite existence issue patent guarantee right practice patent technology commercialize patent product party obtain right patent claim prevent attempt prevent commercialize patented product candidate obtain pharmasset acquisition example aware patent patent application own party allege cover use party successful obtain valid enforceable patent establish infringement patent prevent sell able obtain license patent license need available commercially reasonable term table content gilead successor pharmasset inc party collaboration agreement roche develop psi prodrug treatment chronic hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion roche successfully assert contribute inventorship independently develop file abbreviate new drug application anda market roche point future market product begin compete prior expiration patent marketing activity roche materially reduce revenue expect receive sale adversely affect result operation patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful result operation adversely affect participation event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation examination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient atripla truvada compleraeviplera viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite patent reexamination proceeding ground rejection request brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil file appeal patent authority respond question raise rejection july brazilian patent authority reject application high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer result sell hiv product brazil example indian civil procedure party file opposition grant patent application cover tenofovir disoproxil tenofovir disoproxil fumarate august indian patent office announce decide action allow patent grant file appeal indian patent office intellectual property appellate board application predict outcome proceeding unsuccessful appeal decision appeal pursue indian court system ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india table content addition unsuccessful appeal negative decision indian patent office indian court competitor able continue sell generic tenofovir disoproxil fumarate pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country africa asia include china provide effective enforcement patent thirdparty manufacturer able sell generic version product country abbreviate new drug application file generic manufacturer approval process product fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug example november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate atripla truvada notice relate truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz march file lawsuit teva infringement viread patent additional emtricitabine patent march bms merck file lawsuit teva infringement patent relate efavirenz june receive notice lupin limited lupin submit anda fda request permission manufacture market generic version ranexa notice lupin allege patent associate ranexa invalid unenforceable andor infringed lupin manufacture use sale generic version ranexa july file lawsuit lupin infringement patent ranexa august receive notice sigmapharm lab sigmapharm submit anda fda request permission manufacture market generic version hepsera notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit sigmapharm infringement patent hepsera patent challenge sigmapharm challenge ranbaxy inc ranbaxy pursuant notice receive october patent challenge ranbaxy expire july option filing lawsuit time believe ranbaxy infringe patent table content february receive notice natco pharma limited natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate tamiflu invalid unenforceable andor infringe natcos manufacture use sale generic version tamiflu march roche file lawsuit natco infringement patent associate tamiflu november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic version truvada product notice teva allege patent associate truvada invalid unenforceable andor infringe tevas manufacture use sale generic version truvada january file lawsuit teva seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic version atripla product notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe tevas manufacture use sale generic version atripla february file lawsuit teva seek order prohibition approval and predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada substantially shorten patent cover product invalidate fda approve request manufacture generic version product prior expiration date patent trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention manufacture raw material manufacturing strategy contract party manufacture majority active pharmaceutical ingredient solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility san dimas california edmonton alberta canada cork ireland oceanside california manufacture certain product active pharmaceutical ingredient clinical commercial use table content manufacturing product contract party manufacture certain product clinical commercial purpose include atripla truvada viread hepsera compleraeviplera emtriva ranexa vistide use multiple thirdparty contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient atripla truvada compleraeviplera emtricitabine active pharmaceutical ingredient emtriva active pharmaceutical ingredient atripla truvada compleraeviplera rely single thirdparty manufacturer manufacture active pharmaceutical ingredient ranexa cayston exclusive manufacturer active pharmaceutical ingredient hepsera letairis vistide rely thirdparty contract manufacturer tablet capsulate product example use multiple thirdparty contract manufacturer tablet atripla truvada viread hepsera compleraeviplera ranexa emtriva encapsulation complete thirdparty contract manufacturer rely single thirdparty supplier manufacture letairis tablet manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device require administer cayston lung patient device single supplier single site future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect manufacturing facility san dimas facility manufacture fill package product currently manufacture cayston exclusively san dimas california manufacturing facility unexpected delay qualify new external site expand cayston manufacturing san dimas supply cayston fulfill project demand february suspend access patient new prescription cayston subject certain exception specific medical need exist patient use alternative treatment option able resolve supply shortage result inability manufacture sufficient cayston meet demand revenue expect receive sale cayston reduce single supplier ambisome san dimas facility depend single supplier high quality cholesterol manufacture ambisome fill finish macugen exclusively facility san dimas manufacturing agreement eyetech pfizer eyetech currently provide pegaptanib sodium active pharmaceutical ingredient macugen fill package solid dosage form product include atripla truvada viread compleraeviplera emtriva ranexa finish forms label hepsera facilities san dimas event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need fill package drug product atripla truvada viread cayston finish forms label hepsera emtriva facilities cork ireland perform quality control testing final labeling table content package ambisome final release product european union facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity distribute product european union international market dublin ireland site edmonton facility carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture active pharmaceutical ingredient hepsera letairis vistide exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis oceanside facility acquire design equipped produce biologic compound toxicological phase phase clinical study use facility process development manufacture investigational monoclonal antibody candidate development treatment certain cancer fibrotic disease antibody currently preclinical testing thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product required enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency similar regulation effect country manufacture operation subject routine inspection regulatory agency example january february fda conduct routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston fill finish macugen package solid dosage form product conclusion inspection fda issue form inspectional observation state concern maintenance aseptic processing condition manufacture suite ambisome product environmental maintenance issue san dimas warehousing facility batch sample timeliness completion annual product quality report september san dimas manufacturing facility receive warning letter fda table content detail fda concern ambisome manufacture environment include control system monitor procedure prevent microbiological contamination preventative cleaning equipment maintenance reference certain viread lot letter state concern connect quality procedure control investigation procedure generalize concern effectiveness san dimas quality unit carry responsibility november december fda reinspecte san dimas facility reinspection close additional form observation august fda notify resolve issue raise fda warning letter access supply material need access certain supply product manufacture product delivery material supplier interrupt reason unable purchase sufficient quantity raw material manufacture product unable ship certain product commercial supply supply product candidate development clinical trial example significant portion raw material intermediate manufacture hiv product atripla truvada viread emtriva compleraeviplera supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent approximately total revenue consist primarily tamiflu royalty affect seasonality royalty revenue recognize roche sale tamiflu impact severity flu season product delivery response influenza pandemic operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human table content clinical trial fda accept investigational new drug application drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form new drug application nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory table content inspection manufacturing facility locate california include san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review atripla truvada viread complera receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state aids drug assistance program adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program insufficiency federal state fund state reduce eligibility criterion see continue increase number patient state adap wait list patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general table content europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical generic drug come market face price decrease product country european union government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product example recent hiv treatment guideline united states abroad endorse early diagnosis treatment united states healthcare reform march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act adap discount rebate fee legislation impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug lipitor expect portion excise tax increase estimate impact pharmaceutical excise tax approximately million compare approximately million excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing table content addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment thirdparty payer include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment nonus official purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer result sell hiv product brazil addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china table content sublicense india hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment health safety voluntarily assess publicly report greenhouse gas emission water usage begin action reduce emission usage example establish employee commuter program evaluate energy efficiency building instal lowflow water fixture law regulation implement consideration mitigate effect climate change cause greenhouse gas emission example california air resources board process draft regulation meet state emission target base current information subject finalization propose regulation believe primary risk relate climate change risk increase energy cost energy intensive business anticipate subject cap trade system mitigation measure likely material capital expenditure result operation competitive position subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound activity eliminate risk accidental contamination injury material certain misuse accident involve material lead significant litigation fine penalty implement proactive program reduce minimize risk hazardous material incident information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec street washington call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form current report form amendment report file furnish pursuant section exchange act filing available free charge request table content item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face public announcement datum clinical study evaluate hcvinfecte patient likely cause significant volatility stock price expect receive significant datum clinical trial evaluate investigational nucleotide analog acquire purchase pharmasset hcvinfected individual genotype currently conduct phase study genotype infected hcv patient determine efficacy plus ribavirin population result study available month expect datum evaluate plus ribavirin week genotype treatmentnave patient arm quantum study patient available end quarter expect follow second quarter datum arm electron study involve treatmentnave patient treat week early quarter datum ribavirin treatment week arm quantum study available february announce majority hcv genotype patient prior null response interferoncontaine regiman enrol ongoing electron study experience viral relapse week complete week treatment plus ribavirin patient randomize arm electron study datum available patient time announcement patient experience viral relapse patient relapse reach week posttreatment time point datum indicate treatment genotype patient classify null responder plus ribavirin week sufficient cure disease addition phase study describe recently begin enrol patient phase study evaluate ribavirin genotype infect patient second phase study genotype patient schedule begin enrol week datum phase study indicate small anticipate number patient achieve sustain viral response week posttreatment stock price decline significantly result delay approval treatment genotype andor patient delay andor reduce revenue expect sale develop drug treatment hcv competitive field significant number drug development depend length delay development company develop competitive compound hcv able progress development timeline potentially bring compound market shortly substantial portion revenue derive sale hiv product particularly atripla truvada unable maintain continue increase sale product result operation adversely affect currently dependent sale product treatment hiv infection particularly atripla truvada support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable maintain continue increase hiv product sale result operation likely suffer likely need table content scale operation include spend research development effort year end december atripla truvada product sale billion total revenue able sustain increase growth rate sale hiv product especially atripla truvada number reason include limited follow hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government payer reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand effort drug development inherently risky product candidate fail drug development process example january announce decision terminate phase clinical trial ambrisentan patient idiopathic pulmonary fibrosis ipf april announce decision terminate phase clinical trial aztreonam inhalation solution treatment cystic fibrosis patient burkholderia spp addition marketing application singletablet quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv treatmentnave patient approve fda european medicine agency marketing approval grant significant limitation use unable file marketing application elvitegravir cobicistat currently anticipate timeline marketing approval product grant result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act aids drug assistance program adap discount rebate fee legislation impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole table content pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug lipitor expect portion excise tax increase estimate impact pharmaceutical excise tax approximately million compare approximately million excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program insufficiency federal state fund state reduce eligibility criterion see continue increase number patient state adap wait list patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general table content europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical generic drug come market face price decrease product country european union approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar inability accurately estimate demand product sale fluctuation result inventory level hold wholesaler pharmacie non retail customer difficult accurately forecast sale cause earning fluctuate adversely affect financial result stock price approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesale location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce table content inventory product reduce order wholesaler consequently wholesalers order end user demand change example fourth quarter wholesaler increase inventory level antiviral product quarter wholesaler draw inventory inventory level antiviral product move low end contractual boundary set inventory management agreement inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror patient demand example quarter nonretail purchase drive certain state adap low percentage federal adap fiscal year purchase compare quarter believe decrease drive uncertainty availability federal adap budget lack sufficient state funding second quarter portion year federal budget provide adap result conservative purchase individual state adap quarter federal state budget pressure annual grant cycle federal state adap fund cause adap purchasing pattern reflect patient demand result expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause purchaser reduce inventory product distribution channel case patient level decrease revenue cause fluctuation product sale earning continue trend future face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product joint venture establish glaxosmithkline inc gsk pfizer inc pfizer market fixeddose combination product compete atripla truvada compleraeviplera example lamivudine market joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera face competition generic hiv product compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal recently receive pricing approval italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey viread hepsera treatment chronic hepatitis compete primarily product produce gsk bristolmyer squibb company bms novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck inc merck pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association letairis compete directly table content product produce actelion pharmaceutical inc indirectly pulmonary arterial hypertension product united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug betablocker calcium channel blocker longacte nitrate treatment chronic angina united states cayston competes product market novartis tamiflu compete product sell gsk generic competitor addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve fda june member class compound call endothelin receptor antagonist era pose specific risk include risk birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda european medicines agency comparable regulatory agency country continue clinical trial atripla truvada viread hepsera compleraeviplera emtriva ambisome letairis ranexa cayston currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution table content september president bush sign law food drug administration amendment act significantly expand fdas authority include thing require sponsor market product conduct postapproval clinical study assess know risk signal risk identify unexpected risk mandate labeling change product point product lifecycle base new safety information require sponsor implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example january announce decision terminate phase clinical trial ambrisentan patient ipf april announce decision terminate phase clinical trial aztreonam inhalation solution treatment patient burkholderia spp addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include treatment hepatitis aztreonam inhalation solution treatment bronchiectasis ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type diabete currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption table content relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline rely collaborative relationship major pharmaceutical company development commercialization certain product candidate gilead successor pharmasset inc party collaboration agreement roche develop psi prodrug treatment chronic hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion roche successfully assert contribute inventorship independently develop file abbreviate new drug application anda market roche point future market product begin compete prior expiration patent marketing activity roche materially reduce revenue expect receive sale adversely affect result operation table content april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea november enter agreement gsk provide gsk exclusive commercialization right registration responsibility viread treatment chronic hepatitis china october grant similar right gsk japan saudi arabia success hepsera viread treatment chronic hepatitis territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera viread treatment chronic hepatitis consequently gsk marketing strategy hepsera viread treatment chronic hepatitis influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera viread treatment chronic hepatitis net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera viread treatment chronic hepatitis territory potential revenue territory substantially reduce addition cayston letairis distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support cayston letairis devote resource necessary sell cayston letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient ongoing distribution cayston entirely reliant manufacturer device example manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device addition manufacturer able provide adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit sale cayston adversely affect financial result table content expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter fda andor regulatory agency require clinical testing originally anticipate uneven unexpected spending program cause operating result fluctuate quarter quarter stock price decline success depend significant degree ability protect patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding unpredictable expensive ultimately successful result operation adversely affect event time time certain individual entity challenge patent example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient atripla truvada viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite patent reexamination proceeding ground rejection request brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil table content file appeal patent authority respond question raise rejection july brazilian patent authority reject application high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer result sell hiv product brazil example indian civil procedure party file opposition grant patent application cover tenofovir disoproxil tenofovir disoproxil fumarate august indian patent office announce decide action allow patent grant file appeal indian patent office intellectual property appellate board application predict outcome proceeding unsuccessful appeal decision appeal pursue indian court system ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unsuccessful appeal negative decision indian patent office indian court competitor able continue sell generic tenofovir disoproxil fumarate patent cover ranolazine compound active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapy hepatitis indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension country approval process product fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug example november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate atripla truvada notice relate truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent table content relate emtricitabine patent relate efavirenz march file lawsuit teva infringement viread patent additional emtricitabine patent march bms merck file lawsuit teva infringement patent relate efavirenz june receive notice lupin limited lupin submit anda fda request permission manufacture market generic version ranexa notice lupin allege patent associate ranexa invalid unenforceable andor infringed lupin manufacture use sale generic version ranexa july file lawsuit lupin infringement patent ranexa august receive notice sigmapharm lab sigmapharm submit anda fda request permission manufacture market generic version hepsera notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit sigmapharm infringement patent hepsera patent challenge sigmapharm challenge ranbaxy inc ranbaxy pursuant notice receive october patent challenge ranbaxy expire july option filing lawsuit time believe ranbaxy infringe patent february receive notice natco pharma limited natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate tamiflu invalid unenforceable andor infringe natcos manufacture use sale generic version tamiflu march roche file lawsuit natco infringement patent associate tamiflu november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic version truvada product notice teva allege patent associate truvada invalid unenforceable andor infringe tevas manufacture use sale generic version truvada january file lawsuit teva seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic version atripla product notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe tevas manufacture use sale generic version atripla february file lawsuit teva seek order prohibition approval and predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada substantially shorten patent cover product invalidate fda approve request manufacture generic version product prior expiration date patent success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation leap restrict distribution program design support letairis table content patent claim chemical entity metabolite existence issue patent guarantee right practice patent technology commercialize patent product party obtain right patent claim prevent attempt prevent commercialize patented product candidate obtain pharmasset acquisition example aware patent patent application own party allege cover use party successful obtain valid enforceable patent establish infringement patent prevent sell able obtain license patent license need available commercially reasonable term furthermore use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product example currently manufacture cayston exclusively san dimas california manufacturing facility unexpected delay qualify new external site expand cayston manufacturing san dimas supply cayston fulfill project demand february suspend access patient new prescription cayston subject certain exception specific medical need exist patient use alternative treatment option able resolve supply shortage result inability manufacture sufficient cayston meet demand revenue expect receive sale cayston reduce manufacturing operation subject routine inspection regulatory agency example january february fda conduct routine inspection san dimas manufacturing facility exclusively manufacture cayston ambisome fill finish macugen conclusion inspection fda issue form inspectional observation state concern maintenance table content aseptic processing condition manufacture suite ambisome product environmental maintenance issue san dimas warehousing facility batch sample timeliness completion annual product quality report september san dimas manufacturing facility receive warning letter fda detail fdas concern ambisome manufacture environment include control system monitor procedure prevent microbiological contamination preventative cleaning equipment maintenance reference certain viread lot letter state concern connect quality procedure control investigation procedure generalize concern effectiveness san dimas quality unit carry responsibility november december fda reinspecte san dimas facility reinspection close additional form observation august fda notify resolve issue raise fda warning letter ability successfully manufacture commercialize cayston depend ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture cayston san dimas california party multiproduct manufacturing facility historically fda permit manufacture monobactam multiproduct manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engage contract manufacturer singleproduct facility cayston fda prohibit manufacture monobactam antibiotic like aztreonam multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply cayston anticipate financial result attributable product able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product light global economic downturn increase difficulty purchase certain raw material manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need table content cayston dependent different thirdparty singlesource supplier aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufacture single supplier single site second administer lung patient device single supplier single site disruption delay single supplier adversely affect ability supply cayston sure alternative supplier identify timely manner risk factor entitle ability successfully manufacture commercialize cayston depend ability manufacture multiproduct facility addition depend single supplier highquality cholesterol manufacture ambisome rely single source active pharmaceutical ingredient ranexa hepsera letairis vistide tablete letairis astella llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture hiv product atripla truvada viread compleraeviplera emtriva supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result face credit risk southern european customer adversely affect result operation european product sale governmentowne support customer southern europe specifically greece italy portugal spain historically continue subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable country total approximately billion million past great day million past great day follow thousand december greater great day past day past italy spain portugal greece total result fiscal debt crisis country number day invoice past continue increase line experience pharmaceutical company sell directly hospital historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect example greek government settle substantially outstanding receivables subject bond settlement zerocoupon bond trade discount face table content value december receive total million bond allowance doubtful account adequate cover exposure relate discount bond spain italy portugal actively pursue collection overdue receivables take action necessary enforce legal right payment revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country agreement revenue adversely affect addition establish partnership thirteen indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business expensive litigation government investigation reduce continue reduce earning november receive notice teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate atripla truvada notice relate truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz march file lawsuit teva infringement viread patent additional emtricitabine patent march bms merck file lawsuit teva infringement patent relate efavirenz table content june receive notice lupin submit anda fda request permission manufacture market generic version ranexa notice lupin allege patent associate ranexa invalid unenforceable andor infringed lupin manufacture use sale generic version ranexa july file lawsuit lupin infringement patent ranexa august receive notice sigmapharm submit anda fda request permission manufacture market generic version hepsera notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit sigmapharm infringement patent hepsera patent challenge sigmapharm challenge ranbaxy pursuant notice receive october patent challenge ranbaxy expire july consider option enforce patent february receive notice natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate tamiflu invalid unenforceable andor infringe natcos manufacture use sale generic version tamiflu march roche file lawsuit natco infringement patent associate tamiflu november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic version truvada product notice teva allege patent associate truvada invalid unenforceable andor infringe tevas manufacture use sale generic version truvada january file lawsuit teva seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic version atripla product notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe tevas manufacture use sale generic version atripla february file lawsuit teva seek order prohibition approval and predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla viread canada substantially shorten patent cover product invalidate fda approve request manufacture generic version product prior expiration date patent addition june receive subpoena united states attorney office northern district california request document relate manufacture relate quality distribution practice atripla emtriva hepsera letairis truvada viread complera outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business table content country require grant compulsory license product face generic competition product number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer result sell hiv product brazil addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale change royalty revenue disproportionately affect pretax income earning share gross margin portion revenue derive royalty revenue recognize collaboration agreement party royalty revenue impact pretax income earning share gross margin disproportionately contribution revenue increase decrease royalty revenue material significantly impact operating result example recognize million royalty revenue year end december relate royalty receive sale tamiflu hoffmannla roche ltd hoffmannla roche inc roche royalty revenue represent approximately total revenue represent approximately pretax income period roche tamiflu sale unpredictable variability strong relationship global pandemic planning effort tamiflu royalty increase sharply quarter primarily result pandemic planning initiative worldwide tamiflu royalty second quarter decrease decline pandemic planning initiative worldwide face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability table content costeffective product liability insurance decrease unable maintain sufficient coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely impact addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters palo alto location house majority research development activity san dima oceanside manufacture facility locate california seismically active region carry earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nondeductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition future level spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item unresolved staff comment applicable item property lease facility foster city palo alto fremont san dimas california house manufacturing warehousing activity addition lease facility branford connecticut princeton new jersey durham north carolina seattle washington house administrative activity table content international headquarter include commercial medical administrative facility locate lease london area united kingdom manufacturing facility cork ireland primarily use solid dose tablet manufacturing antiviral product product packaging activity lease facility cork share service lease facility dublin area ireland house distribution activity manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process manufacture facility oceanside california design equipped produce biologic compound toxicological phase phase clinical study use facility process development manufacture investigational monoclonal antibody candidate development treatment certain cancer fibrotic disease antibody currently preclinical testing lease additional facility house commercial medical administrative activity australia austria belgium canada france germany greece hong kong ireland italy netherlands poland portugal spain south korea sweden switzerland turkey united kingdom lease office shanghai china provide source manufacturing support primarily relate commercial purchase active pharmaceutical ingredient believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding november receive notice teva pharmaceutical teva submit abbreviate new drug application anda food drug administration fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit district court new york teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate atripla truvada notice relate atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz notice relate truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine march file lawsuit teva infringement viread patent additional emtricitabine patent march bristolmyers squibb company merck inc file lawsuit teva infringement patent relate efavirenz june receive notice lupin limited lupin submit anda fda request permission manufacture market generic version ranexa notice lupin allege table content patent associate ranexa invalid unenforceable andor infringed lupin manufacture use sale generic version ranexa july file lawsuit district court new jersey lupin infringement patent ranexa august receive notice sigmapharm lab sigmapharm submit anda fda request permission manufacture market generic version hepsera notice sigmapharm allege patent associate hepsera invalid unenforceable andor infringe sigmapharm manufacture use sale generic version hepsera september file lawsuit district court new jersey sigmapharm infringement patent hepsera patent challenge sigmapharm challenge ranbaxy inc ranbaxy pursuant notice receive october patent challenge ranbaxy expire july option filing lawsuit time believe ranbaxy infringe patent february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate tamiflu invalid unenforceable andor infringe natcos manufacture use sale generic version tamiflu march hoffmannla roche ltd file lawsuit district court new jersey natco infringement patent associate tamiflu november receive notice teva submit abbreviate new drug submission ands canadian ministry health request permission manufacture market generic version truvada product notice teva allege patent associate truvada invalid unenforceable andor infringe tevas manufacture use sale generic version truvada january file lawsuit canadian federal court teva seek order prohibition approval and december receive notice teva submit ands canadian ministry health request permission manufacture market generic version atripla product notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe tevas manufacture use sale generic version atripla february file lawsuit canadian federal court teva seek order prohibition approval and predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada substantially shorten patent cover product invalidate fda approve request manufacture generic version product prior expiration date patent june receive subpoena united states attorney office northern district california request document relate manufacture relate quality distribution practice atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range loss determine give early stage inquiry party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation item safety disclosure applicable table content item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception expect retain earning primarily use operation expansion business anticipate pay cash dividend near future effort continue return value stockholder minimize dilution stock issuance january board directors board authorize threeyear billion stock repurchase program commence september completion stock repurchase program intend use additional authorization repurchase share time time offset dilution create share issue employee stock plan repurchase share december repurchase million common stock january stock repurchase program spend total billion repurchase retire million share common stock average purchase price share item note consolidated financial statement include annual report information stock repurchase program table content performance graph follow graph compare total stockholder return past year index standard poor stock index label index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index index december table content issuer purchase equity security effort continue return value stockholder minimize dilution stock issuance january board authorize threeyear billion stock repurchase program commence september completion stock repurchase program intend use additional authorization repurchase share time time offset dilution create share issue employee stock plan repurchase share december repurchase million common stock january stock repurchase program spend total billion repurchase retire million share common stock average purchase price share item note consolidated financial statement include annual report information stock repurchase program table summarize stock repurchase activity month end december thousands share amount total number maximum fair value share purchase share total number average price pay publicly purchase share purchase share announce programs program october october november november december december total difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note unsecure senior note retain earning total stockholder equity record million impairment charge research development expense relate certain inprocess research development iprd asset acquire cgi pharmaceuticals inc item note consolidated financial statement include annual report record million impairment charge expense relate certain iprd asset acquire therapeutics inc therapeutic item note consolidated financial statement include annual report complete acquisition asset navita asset llc relate cicletanine business aggregate purchase price million allocate purchase iprd table content gilead sciences inc select consolidated financial datacontinue complete acquisition therapeutic recognize consideration transfer billion primarily record intangible asset item note consolidated financial statement include annual report issue billion principal senior unsecured note register offering item note consolidated financial statement include annual report issue billion principal convertible senior note private placement item note consolidated financial statement include annual report table content item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hivaid liver disease hepatitis virus hbv hepatitis virus hcv cardiovascularmetabolic respiratory condition headquarter foster city california operations north america europe asia pacific continue seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise atripla truvada viread emtriva compleraeviplera hepsera ambisome letairis ranexa cayston vistide addition sell distribute certain product corporate partner royaltypaye collaborative agreement example hoffmannla roche ltd hoffmannla roche inc roche market tamiflu glaxosmithkline inc gsk markets hepsera viread certain territory outside united states gsk market volibris outside united states astellas pharma inc markets ambisome united states canada astellas llc market lexiscan injection united states rapidscan pharma solutions inc market rapiscan certain territory outside united states menarini international operation luxembourg markets ranexa certain territory outside united states japan tobacco inc japan tobacco market truvada viread emtriva japan business highlight continue advance pipeline internal program therapeutic area augment effort strategic investment acquisition inlicense opportunity collaboration liver disease area acquisition pharmasset inc pharmasset early mark significant opportunity continue develop bestinclass drug believe combination exist internal research program recent partnership acquisition drive research development effort accelerate product pipeline continue bring innovative therapy individual world live unmet medical need summary key accomplishment receive marketing approval begin launch compleraeviplera second singletablet regimen treatment hiv united states canada certain country european union submit new drug application nda quad singletablet regimen elvitegravir cobicistat emtricitabine tenofovir disoproxil fumarate treatment hiv week phase study conclude obtain food drug administration fda agreement revision letairis label subsequently change sale trajectory product table content progress investigational nucleotide reverse transcriptase inhibitor complete collaborative agreement hiv field set stage generation singletablet regimen accelerate timeline develop alloral hcv regiman result pharmasset acquisition complete arresto bioscience inc arresto calistoga pharmaceuticals inc calistoga acquisition acquire oceanside california facility biologic manufacturing support advance clinical study oncology new potential product offering new drug application area hiv continue effort expand product offering singletablet regimen launch compleraeviplera submission quad regulatory approval united states europe august receive fda approval complera treatment hiv infection treatmentnave adult complera combine antiretroviral medication daily tabletour truvada fixeddose combination emtricitabine tenofovir disoproxil fumarate edurant rilpivirine market tibotec pharmaceutical tibotec november receive marketing approval product europe product market eviplera october submit nda fda marketing approval quad treatment hiv infection adult subsequently fda accept nda set target review date august prescription drug user fee act pdufa fda indicate panel convene provide expert advice application submit marketing authorisation application quad treatment hiv infection adult european medicine agency november december announce phase clinical trial pharmacoenhance boost agent cobicistat meet week primary object non inferiority cobicistat increase blood level certain hiv medicine allow pill oncedaily dose study indicate week treatment percent patient take regiman cobicistatbooste atazanavir plus truvada achieve comparable result patient taking ritonavirbooste atazanavir plus truvada december announce phase clinical trial result show elvitegravir integrase inhibitor evaluate treatment hiv infection noninferior integrase inhibitor raltegravir year therapy treatmentexperience patient result study indicate elvitegravir potential new oncedaily treatment option hiv develop resistance therapy acquisition january complete acquisition arresto million plus potential future payment base achievement certain sale level arresto privatelyheld developmentstage biotechnology company base palo alto california focus develop antibody potential treatment fibrotic disease cancer lead product acquisition humanize monoclonal antibody mab target human lysyl oxidaselike loxl protein addition ongoing phase study liver fibrosis myelofibrosis colorectal cancer pancreatic cancer phase study conduct evaluate patient idiopathic pulmonary fibrosis april acquire calistoga million plus potential payment million base achievement certain milestone calistoga privatelyheld biotechnology company base seattle washington focus development medicine treat cancer inflammatory disease table content portfolio proprietary compound acquisition selectively target isoform phosphoinositide kinase pik calistogas lead product candidate firstinclass specific inhibitor pik delta isoform pik delta preferentially express leukocyte involve variety inflammatory autoimmune disease hematological cancer november enter agreement acquire pharmasset billion acquisition finance cash hand bank debt senior unsecured note acquisition complete january pharmasset clinicalstage pharmaceutical company locate princeton new jersey commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv pharmasset research development effort focus nucleosidetide analogs class compound act alternative substrate viral polymerase inhibit viral replication inlicense collaboration june enter agreement tibotec development commercialization new fixeddose combination product contain cobicistat tibotec protease inhibitor prezista darunavir indicate treatment hiv prezista currently coadministere ritonavir combination antiretroviral agent october enter agreement boehringer ingelheim worldwide rights research development commercialization bi novel noncatalytic site integrase inhibitor hiv include lead compound evaluate phase doseescalation study assess bioavailability pharmacokinetic healthy volunteer october enter agreement globeimmune inc license development commercialization therapeutic vaccine product use conjunction viread oral therapy treatment chronic hbv infection october enter agreement bristolmyer squibb company bms licensing development commercialization fixeddose combination contain bmss protease inhibitor reyataz atazanavir sulfate cobicistat currently study atazanavir cobicistat phase study hiv treatmentnave patient november enter agreement tibotec development commercialization singletablet regiman combine tibotecs prezista emtriva cobicistat financial highlight spite challenge macroeconomic environment continue grow business achieve total product sale billion increase growth product sale primarily drive growth antiviral franchise sale increase billion compare prior year sale product comprise primarily ambisome ranexa letairis reach billion increase compare prior year total revenue grow billion product sale growth partially offset decline royalty revenue collaboration corporate partner million decrease primarily low tamiflu royalty pandemic planning initiative worldwide decline gross margin decrease primarily annual selling price adjustment percentage share atripla pay partner expense billion billion increase million increase primarily cost relate clinical study impact high headcount table content expense associate acquisition collaboration ongoing growth business sell general administrative sga expense billion billion increase million increase primarily increase expense associate ongoing growth business pharmaceutical excise tax result healthcare reform increase bad debt provision slow collection certain southern european country net income billion decrease billion primarily investment exist clinical program acquisition inlicense collaboration agreement low tamiflu royalty roche result decline pandemic planning initiative worldwide diluted earning share increase incorporate impact share repurchase year financing activity cash cash equivalent marketable security increase billion total billion december primary source cash cash equivalent marketable security operate cash flow billion billion proceed issuance senior unsecured note billion raise december partially fund pharmasset acquisition key use cash year include billion repurchase common stock stock repurchase program million repayment convertible senior note million acquisition activity complete billion stock repurchase program commence share repurchase threeyear billion stock repurchase program authorize board director january spend total billion cash repurchase retire million share common stock average purchase price share subsequent event january raise billion bank debt partially fund acquisition pharmasset acquire pharmasset billion cash tender offer subsequent merger closed january pharmasset lead compound nucleotide analog hcvinfecte individual genotype know expect receive significant datum clinical trial evaluate february announce datum indicate ribavirin treatment genotype patient prior null response interferoncontaine regiman week sufficient cure disease currently conduct additional phase study hcv infected genotype patient include treatmentnave patient result expect end quarter second quarter early quarter outlook operating objective include increase market share commercial product continue strengthen pipeline internally develop andor externally inlicense purchase opportunity strengthen key alliance standpoint continue execute pipeline development particular focus innovative hiv singletablet regimen patient progression hcv molecule clinic new initiative oncology inflammation expect publicly announce additional data set relate development treatment hcv affect cost duration development effort table content commercial standpoint number internal external initiative intend promote continue growth franchise hiv area scientific argument diagnose treat patient early strong reason use singletablet regimen compelling medically practically extension ryan white treatment act provide stable funding aid drug assistance program adap united state continue roll compleraeviplera world subject fda approval quad bring singletablet regimen individual live hiv launch truvadarilpivirine singletablet regimen treatment hiv complera united states canada eviplera united kingdom austria expect continue uptake complera united states canada launch eviplera europe quad review fda pdufa date august assume approval expect launch product september expect quad contribute incremental revenue hiv franchise hbv area continue support educational promotional activity focus asian community highlight need screen diagnose link patient care cardiovascular area continue effort raise awareness gilead pulmonary arterial hypertension cardiology community believe help grow revenue letairis ranexa mindful conditions current macroeconomic environment affect ability achieve goal factor affect business include future change healthcare reform united states continuation worsen global economic condition patent expiration competitive product launch generic competitor continue government pricing pressure internationally potential volatility foreign currency exchange rate continue monitor condition adjust business process appropriate mitigate risk business believe success experienced enable continue build financially sound business model allow continue expand commercial activity maintain quality compliance continue grow business remain focused profitable revenue growth prudent expense management believe enable solid execution operating objective critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition intangible asset allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement table content revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program reduction settle invoice directly chargeback wholesaler government rebate invoice directly record accrue government rebate consolidated balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable pay rebate country outside united states date payment foreign government represent significant portion total government rebate government program united states estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate billion billion million respectively represent total gross product sale respectively deduct gross product sale believe methodology use estimate sale allowance government price reduction reasonable appropriate give current fact circumstance actual result differ base current information available actual government rebate claim period vary approximately estimate record period december accrue government rebate million million respectively accrue government rebate allowance government chargeback million million respectively record account receivable follow table summarize aggregate activity government rebate allowance accrue liability account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total table content intangible asset conjunction business combination complete record intangible asset primarily relate market product iprd project goodwill recognition measurement asset acquire liability assume business combination identifiable intangible asset relate market product iprd project measure respective fair value acquisition date believe fair value assign acquire intangible asset base reasonable estimate assumption give available fact circumstance acquisition date discount cash flow model value intangible asset model require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination goodwill intangible asset determine indefinite useful life amortize require test impairment annually test goodwill indefinitelive intangible asset impairment annual basis annual test aware event occur change circumstance indicate reduction fair value asset carry amount december billion indefinitelive intangible asset consist billion goodwill result business combination million intangible asset relate iprd project acquire arresto calistoga intangible asset finite useful life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable amortize intangible asset relate ranexa product acquire therapeutic estimate useful life amortization rate derive forecast future product sale ranexa product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast prospectively update rate amortize intangible asset relate ranexa increase future cost good sell record amortization expense amortize intangible asset relate lexiscan product acquire therapeutic estimate useful life cost good sell straightline basis give current lexiscan revenue consist royalty receive collaboration partner lack ongoing access visibility partner future sale forecast reasonable estimate amortization rate forecasted product sale approach december million net unamortized finitelive intangible asset consist primarily intangible asset relate market product acquire therapeutic judgment existence impairment indicator base historical project future operating result extent manner use acquire asset legal regulatory factor event overall business strategy market economic trend event occur future cause conclude impairment indicator exist certain intangible asset impair financial condition result operation adversely impact table content fourth quarter record million impairment charge relate certain iprd asset acquire therapeutic future plan develop deem future use market participant charge relate adentri tecadenoson program record expense majority impairment charge relate program product candidate phase clinical study treatment diabetes hypertriglyceridemia terminate fourth quarter unfavorable result pharmacokinetic pharmacodynamic test demonstrate limited effectiveness compound patient give result believe alternative future use market participant fourth quarter record million impairment charge relate certain iprd asset acquire cgi impairment charge result change anticipate market share relate syk compound allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require believe allowance doubtful account adequate significant deterioration factor materially change expectation result increase allowance doubtful account prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory university emory hiv indication base present value future royalty obligation expect pay emory assume certain expect future level product sale incorporate emtricitabine present value future royalty obligation derive weightedaverage cost capital review periodically expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty potential indicator impairment include launch significant product competitor significant deviation recognize product sale compare forecast product safety issue recall amortize prepay royalty base effective royalty rate derive forecast future hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future cost good sell record amortization expense december prepay royalty asset relate emtricitabine royalty pay emory million million respectively amortization expense relate prepay royalty asset million million million year end december respectively clinical trial accrual record accrual estimate clinical study cost clinical study perform thirdparty contract research organization cro cost significant component expense table content incur cro cost million million million respectively accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management startup cost usually occur month contract execute milestone event drive nature remain clinical activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase clinical study year complex phase clinical study average length contract upper end range order provide longterm safety efficacy datum support commercial launch atripla truvada viread compleraeviplera hepsera emtriva letairis ranexa material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate december difference actual estimate activity level particular study material management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination future effective income tax rate affect factor change tax law regulation rate change interpretation exist law regulation impact accounting stockbase compensation change international organization change overall level income tax record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period table content december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position stockbase compensation measure sharebase payment employee director include grant stock option base relative fair value fair value award grant stock option plan employee stock purchase plan estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life fair value restrict stock unit rsus equal closing price common stock grant date rsus vest ratably annual basis year grant date award grant prior year grant date award grant grant performancebase restricted stock unit value monte carlo valuation method vest achievement specify market performance goal relative pre determined peer group actual number common share ultimately issue calculated multiplying number performance unit payout percentage range performance awards vest committee subcommittee board determine achieve specified market performance goal stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach unvested stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation additional paidin capital apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic year end december recognize stockbased compensation expense million million million respectively operate expense table content capitalize million million million respectively inventory december million million million stockbase compensation cost include inventory respectively december unrecognize stockbase compensation expense million relate unvested stock option expect expense estimate weightedaverage period year unrecognized stock base compensation expense million relate rsus expect expense estimate weighted average period year result operation total revenue total revenue billion billion billion include total revenue product sale royalty revenue contract revenue increase total revenue drive growth product sale total product sale billion increase total product sale billion drive primarily antiviral franchise result continued growth sale atripla truvada increase product sale reflect sale growth nonantiviral product primarily ambisome ranexa letairis cayston reach billion mark compare million increase product sale partially offset decline tamiflu royalty roche decline pandemic planning initiative worldwide total product sale increase compare billion primarily drive growth atripla truvada sale product sale united states increase compare primarily drive continued sale growth antiviral franchise introduction complera partially offset ongoing impact healthcare reform increase reflect sale growth nonantiviral franchise ranexa sale contribute million product sale increase compare letairis sale contribute million product sale increase compare cayston contribute million product sale increase compare product sale europe increase compare primarily drive sale growth antiviral franchise increase partially offset impact price reduction austerity measure certain european country antiviral product sale europe total billion increase compare billion drive primarily sale atripla truvada foreign currency exchange net hedge unfavorable impact european product sale compare significant percentage product sale continue denominate foreign currency face exposure adverse movement foreign currency exchange rate foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro foreign currency exchange net hedge favorable impact million revenue compare unfavorable impact million revenue compare expect total product sale continue grow expect realize year impact relate new product compleraeviplera expect launch quad united states september table content product sale follow table summarize period period change product sale thousand change change antiviral product atripla truvada viread hepsera compleraeviplera emtriva total antiviral product ambisome letairis ranexa total product sale antiviral product antiviral product sale increase compare compare atripla atripla sale increase compare drive primarily sale growth europe united states atripla sale increase compare drive primarily sale growth united states europe benefit launch atripla france second quarter atripla sale include efavirenz component gross margin zero efavirenz portion atripla sale approximately billion billion million respectively atripla sale account total antiviral product sale respectively truvada truvada sales increase compare drive primarily sale growth europe united states truvada sales increase compare drive primarily sale growth united states europe truvada sale account total antiviral product sale respectively antiviral product antiviral product sale include product sale viread hepsera compleraeviplera emtriva decrease compare primarily decrease hepsera sale partially offset launch compleraeviplera follow fda approval august european commission approval november antiviral product sale decrease compare primarily decrease hepsera sale partially offset sale growth viread ambisome sale ambisome increase compare drive primarily sale growth latin america canada europe sale ambisome increase compare drive primarily sale growth certain market outside united states partially offset unfavorable foreign table content currency exchange impact ambisome product sale united states canada relate solely sale ambisome astella pharma inc record manufacturing cost letairis sale letairis increase compare compare drive primarily sale growth new patient enrollment increase follow fdas approval march remove liver toxicity language box warning ranexa sale ranexa increase compare compare drive primarily sale growth royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue historically significant source royalty revenue sale tamiflu roche recognize royalty tamiflu sale roche quarter follow quarter tamiflu sale recognize roche royalty revenue decline compare primarily low tamiflu royalty roche royalty revenue increase compare drive primarily increase royalty revenue include royalty gsk hepsera royalty astella llc lexiscan royalties japan tobacco truvada partially offset low tamiflu royalty roche tamiflu royalty second quarter decrease decline pandemic planning initiative worldwide tamiflu royalty roche contribute million million million total royalty revenue respectively cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin decrease compare primarily annual selling price adjustment percentage share atripla pay partner product gross margin consistent product gross margin expect product gross margin lower compare primarily product mix expect high proportion atripla sale partially offset increase product gross margin relate year impact sale compleraeviplera anticipate launch quad september table content research development expense manage expense identify research development activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource similar consideration continually review pipeline status development necessary reallocate resource portfolio believe good support future growth business follow table summarize period period change expense thousand change change research development expense summarize consist primarily personnel cost include salary benefit stockbase compensation clinical study perform cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facilitiesrelate cost follow table provide breakout expense major cost type thousand clinical study outside service personnel expense impairment restructuring charge total expense increase million compare primarily million increase clinical study outside service relate study progression liver disease hiv new investment oncology inflammation new inlicense agreement milestone ongoing collaboration million increase personnel expense high headcount increase expense include research process development manufacturing support clinical study ongoing growth business partially offset decrease impairment charge expense increase million compare primarily impairment charge million record relate iprd asset acquire therapeutic million clinical study expense relate increase hiv research activity million compensation benefit expense majority impairment charge relate program product candidate phase clinical study treatment diabetes hypertriglyceridemia terminate fourth quarter unfavorable result pharmacokinetic pharmacodynamic test demonstrate limited effectiveness compound patient give result believe alternative future use market participant increase expense partially offset million time certain clinical study million low expense reimbursement relate collaboration tibotec expect expense increase level continued investment internal collaborative effort anticipate product candidate progress advanced phase clinical study add clinical development program pipeline table content sell general administrative expense follow table summarize period period change sga expense thousand change change sell general administrative sga expense comprise primarily compensation benefit associate sale marketing finance human resource legal administrative personnel facility overhead cost outside marketing advertising legal expense general administrative cost sga expense increase million compare primarily increase contract legal professional service million pharmaceutical excise tax million result healthcare reform increase compensation benefit expense million result high headcount support expand commercial activity promotional cost million drive expand sale marketing activity bad debt provision million associate slow collection southern european country sga expense increase million compare primarily increase compensation benefit expense million result high headcount support expand commercial activity increase contract professional service expense million drive primarily expand sale marketing activity million relate facility equipment expense expect sga expense increase level increase investment support continued growth franchise increase pharmaceutical excise tax believe appropriate sga infrastructure support growth business restructuring expense second quarter approve communicate plan close research operation durham north carolina consolidate liver disease research activity foster city california believe plan allow employee collaborate effectively advance program liver disease area record total million million restructuring expense sga expense respectively relate employee severance facilitiesrelate expense plan december close operation durham incur expect incur additional significant cost connection plan second quarter approve plan realize certain synergy result therapeutics acquisition realign cardiovascular operation eliminate redundancy record million million restructuring expense sga expense respectively relate employee severance relocation lease termination cost facilitiesrelate expense record million restructuring expense sga relate facilitiesrelate expense total cost incur plan million million sga expense respectively incur expect incur additional significant cost connection plan interest income net record interest income net million million million respectively increase interest income net compare drive primarily favorable net foreign currency exchange impact increase interest income partially offset increase cost relate hedging activity increase interest income net compare drive primarily decrease cost relate hedging activity table content expect interest income decrease spend cash cash equivalent marketable security partially fund pharmasset acquisition close january interest expense interest expense million million million respectively increase interest expense compare primarily issuance convertible senior note billion july issuance senior unsecured note billion march issuance senior unsecured note billion december bridge financing associate acquisition pharmasset increase partially offset maturity convertible senior note aggregate principal balance million increase interest expense compare primarily issuance senior convertible note billion july expect interest expense increase additional debt issue connection acquisition pharmasset include billion senior unsecured note issue december billion bank debt raise subsequent december provision income taxis provision income taxis million billion million respectively effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis nondeductible pharmaceutical excise tax provide income taxis undistribute earning foreign operation intend permanently reinveste effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis effective tax rate differ federal statutory rate primarily tax credit resolution certain tax position tax authority certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis revaluation certain state tax asset relate integration therapeutic liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future cash cash equivalent marketable security increase significantly fourth quarter issue senior unsecured note total net proceed billion fund billion acquisition pharmasset close january additional information describe cash cash equivalent marketable security working capital primary source use cash table content follow table summarize cash cash equivalent marketable security work capital cash flow activity end period present thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion december increase primarily attributable issuance senior unsecured note total net proceed billion cash provide operation billion increase partially offset billion repurchase common stock stock repurchase program million repay convertible senior note million recent acquisition arresto calistoga net proceed relate senior unsecured note issue december fund acquisition pharmasset january cash cash equivalent marketable security total billion december increase billion december increase primarily attributable net cash provide operation billion net proceed billion issuance convertible senior note partially offset billion repurchase common stock stock repurchase program work capital work capital billion december increase billion work capital december primarily attributable increase billion cash cash equivalent shortterm marketable security result billion issuance senior unsecured note december sale longterm marketable security anticipation acquisition pharmasset decrease million current portion longterm debt obligation net primarily repayment convertible senior note work capital billion december increase million work capital december increase primarily attributable increase million cash cash equivalent shortterm marketable security increase million account receivable net primarily drive increase product sale increase million inventory primarily purchase efavirenz estimate net sell price bms table content increase partially offset increase million current portion convertible senior note net longterm obligation reclassification convertible senior note current liability cash provide operating activity cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million defer income taxis million net cash inflow relate change operate asset liability partially offset million excess tax benefit stock option exercise reclassify cash financing activity cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million iprd impairment expense million tax benefit employee stock plan partially offset million net cash outflow relate change operate asset liabilitie million excess tax benefit stock option exercise reclassify cash financing activity cash provide operating activity billion primarily related net income billion adjust noncash item million stockbase compensation expense million amortization expense cash provide investing activity cash provide investing activity billion consist net proceed billion relate sale marketable security connection acquisition pharmasset partially offset million acquisition arresto calistoga million capital expenditure cash investing activity billion drive net use billion purchase marketable security million acquisition cgi million capital expenditure cash investing activity billion drive cash acquisition therapeutic billion net cash acquire net use million purchase marketable security million capital expenditure year capital expenditure include purchase office building approximately acre land locate foster city california cash provide financing activity cash provide financing activity billion drive primarily issuance billion senior unsecured note billion raise december partially fund pharmasset acquisition net issuance cost million proceed issuance common stock employee stock plan cash proceed partially offset billion repurchase common stock stock repurchase program include commission million repay convertible senior note cash financing activity billion drive primarily billion repurchase common stock stock repurchase program million purchase note hedge relate convertible senior note cash outflow partially offset billion net proceed issuance note million proceed sale warrant relate note million proceed issuance common stock employee stock plan table content cash financing activity billion drive primarily million repurchase common stock stock repurchase program million extinguish convertible senior note assume acquisition therapeutics cash outflow partially offset proceed million issuance common stock employee stock plan complete threeyear billion stock repurchase program time initiate purchase january threeyear billion stock repurchase program complete program repurchase retire total million share common stock average purchase price share december remain authorize stock repurchase repurchase program billion longterm debt eligible borrow aggregate billion revolving credit loan amend restate credit agreement credit agreement include subfacility swingline loan letter credit december million letter credit outstanding billion credit agreement january fully repay outstanding obligation credit agreement time credit agreement terminate january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement fiveyear revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow aggregate principal billion follow million year revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin base rate plus applicable margin define applicable credit agreement reduce commitment prepay loan agreement time premium penalty fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility year revolve credit agreement terminate amount owe thereunder shall payable january shortterm revolve credit agreement terminate amount owe thereunder shall payable january request maturity date extend january principal repayment installment term loan credit agreement payable specify term loan credit agreement final principal installment payment payable january december issue senior unsecured note register offering aggregate principal billion partially fund acquisition pharmasset note pay interest fix annual rate range convertible senior note mature repay aggregate principal balance million pay million cash relate conversion spread mature note represent conversion value excess principal receive million cash relate convertible note hedge warrant relate convertible senior note expire august table content march issue senior unsecured note april register offering aggregate principal billion note pay interest fix annual rate believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require assure available favorable term balance sheet arrangement balance sheet arrangement contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december thousands payment period contractual obligation total year year year year longterm debt operating lease obligation capital commitment purchase obligation clinical trial total longterm debt obligation include future interest payment base fix rate convertible senior note respectively longterm debt obligation include future interest payment base fix rate senior unsecured note december december april december december respectively december aggregate carry value convertible note senior unsecured note billion billion respectively table content december firm capital project commitment approximately million primarily relate facility improvement project december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement actual purchase expect significantly exceed amount addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability million december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position unrecognize tax benefit include longterm income taxis payable noncurrent defer tax asset consolidate balance sheet include table recent accounting pronouncement financial accounting standard board fasb issue amendment exist standard fair value measurement achieve common guidance generally accept accounting principle international financial reporting standard addition amend standard revise certain requirement measure fair value disclosure fair value measurement require additional fair value measurement intend establish valuation standard affect valuation practice outside financial reporting update standard effective begin quarter early adoption permit adoption amendment material impact consolidate financial statement june fasb issue update exist standard comprehensive income presentation item comprehensive income oci prominent update standard prohibit current presentation oci statement stockholder equity instead provide public company option present oci continuous statement comprehensive income separate consecutive statement additionally update require reclassification adjustment display face financial statement oci report december fasb issue update indefinitely defer specific requirement presenting reclassification adjustment oci net income oci face financial statement deferral period exist requirement presentation reclassification adjustment continue follow update standard effective begin quarter adoption update standard impact presentation consolidate financial statement impact financial position result operation september fasb issue new accounting guidance intend simplify goodwill impairment testing entity allow perform qualitative assessment goodwill impairment determine quantitative assessment necessary guidance effective goodwill impairment test perform interim annual period fiscal year begin december standard effective begin quarter adoption guidance material impact consolidate financial statement table content december fasb issue new standard address disclosure requirement offset financial derivative instrument relate arrangement enable user financial statement understand effect arrangement company financial position update require company disclose net gross amount relevant asset liability offset note financial statement update standard effective begin quarter apply retrospectively comparative period present believe adoption standard material impact consolidate financial statement table content item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business significant percentage product sale denominate foreign currency enter foreign currency exchange forward option contract partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge follow table summarize notional amount weightedaverage currency exchange rate fair value open foreign currency exchange forward contract december foreign currency exchange option contract outstanding december contract maturity month weightedaverage rate state term dollar foreign currency fair value represent estimate settlement amount december notional amount fair value dollar thousand foreign currency exchange forward contract december december weight weight average average notional settlement notional settlement currency price fair value price fair value euro british pound canadian dollar australian dollar swiss franc danish krone swedish krone norwegian krone new zealand dollar turkish lira polish zloty total table content interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december dollar thousand total fair year end december value december total asset availableforsale debt security average interest rate liability longterm debt average interest rate april issue convertible senior note private placement pursuant rule securities act amend note issue par bear interest rate convert share common stock subject certain circumstance july issue convertible senior note private placement pursuant rule securities act amend note issued par bear interest rate respectively convert share common stock subject certain circumstance march issue senior unsecured note april register offering note pay interest fix annual rate december issue senior unsecured note december register offering note pay interest fix annual rate range connection fund billion acquisition pharmasset liquidate approximately billion investment portfolio late proceed sale reinveste money market fund total billion december interest rate risk money market fund low exclude balance table interest rate sensitive instrument continue invest exist portfolio security similar profile amounts invest generally small short investment horizon credit risk december hold approximately million auction rate security availableforsale longterm marketable security auction rate security comprise total table content cash cash equivalent marketable security december begin observe fail auction auction rate security underlie asset comprise student loan auction rate security include subject fail auction currently rate aaa consistent high quality rating require investment policy support federal government federal family education loan program overcollateralize auction rate security reset seven day maturity date range annual interest rate range december auction rate security continue earn interest auction continue fail security invest unable liquidate auction rate security par need desire access fund invest security base expect operating cash flow access fund credit facility believe able hold security recovery auction market relate security final maturity result anticipate current illiquidity auction rate security material effect cash requirement work capital december hold greek governmentissue bond estimate fair value approximately million availableforsale long term marketable security greek government agree settle majority age outstanding account receivable zerocoupon bond currently bond trade infrequently open market substantial discount face value believe able hold security maturity result anticipate illiquidity security material effect cash requirement work capital light volatility development see financial market continue review cash equivalent marketable security carefully strive invest prudently believe maintain primary goal investment policy safety preservation principal diversification risk liquidity help protect risk credit market allow continue meet operate cash flow requirement execute strategic opportunity subject credit risk account receivable relate product sale account receivable balance december billion compare billion december majority trade account receivable arise product sale united states europe december account receivables southern europe specifically greece italy portugal spain total approximately billion million great day past million great day past item financial statement supplementary datum financial statement require item set forth begin annual report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule securities exchange act table content amend exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report effectiveness internal control financial reporting december report audit internal control financial reporting appear change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting complete implementation new enterprise resource planning erp system fourth quarter implementation undertake response identify deficiency weakness internal control financial reporting undertake establish scalable foundation core business process item information applicable table content report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february table content iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee qualification nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service table content item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document agreement plan merger registrant apex merger sub inc therapeutics inc date march agreement plan merger registrant cougar merger sub inc cgi pharmaceuticals inc date june agreement plan merger registrant arroyo merger sub inc arresto biosciences inc date december agreement plan merger registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc shareholder representative service llc stockholder agent date february amendment agreement plan merger registrant gilead biopharmaceutics ireland corporation hot springs acquisition corp calistoga pharmaceuticals inc shareholder representative service llc stockholder agent enter march agreement plan merger registrant merger sub pharmasset inc date november restate certificate incorporation registrant amend certificate designation series junior participate prefer stock registrant certificate amendment certificate designation series junior participate prefer stock registrant amend restate bylaw registrant amend restate reference exhibit exhibit exhibit exhibit amend restate right agreement registrant chasemellon shareholder services llc date october table content exhibit exhibit footnote number description document amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date october second amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date july indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date july indenture date march registrant wells fargo national association trustee supplemental indenture date march registrant wells fargo national association trustee form note include exhibit second supplemental indenture date december registrant wells fargo national association trustee form note include exhibit form note include exhibit form note include exhibit form note include exhibit confirmation otc convertible note hedge relate note date april amend restate april registrant bank america confirmation otc warrant transaction date april amend restate april registrant bank america warrants expire confirmation otc convertible note hedge relate note date july registrant goldman sachs confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc convertible note hedge relate note date july registrant goldman sachs confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc warrant transaction date july registrant goldman sach warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrant expiring table content exhibit exhibit footnote number description document confirmation otc warrant transaction date july registrant goldman sach warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrants expire confirmation otc additional convertible note hedge relate note date august registrant goldman sachs confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge relate note date august registrant goldman sachs confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction date august registrant goldman sach warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expire confirmation otc additional warrant transaction date august registrant goldman sach warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association year revolve credit facility credit agreement registrant gilead biopharmaceutics ireland corporation borrowers bank america administrative agent swing line lender issuer certain lender party thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank royal bank canada wells fargo bank codocumentation agent date january table content exhibit exhibit footnote number description document shortterm revolve credit facility credit agreement registrant gilead biopharmaceutics ireland corporation borrowers bank america administrative agent certain lender party thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank royal bank canada wells fargo bank codocumentation agent date january term loan facility credit agreement registrant borrower bank america certain lender party thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank royal bank canada wells fargo bank codocumentation agent date january parent guaranty agreement year revolve credit facility date january registrant parent guaranty agreement shortterm revolve credit facility date january registrant gilead sciences inc stock option plan amend january form option agreement stock option plan gilead sciences inc nonemployee directors stock option plan amend january form option agreement gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amend form employee stock option agreement equity incentive plan grant prior february form employee stock option agreement equity incentive plan grant february april form employee stock option agreement equity incentive plan grant commencing form employee stock option agreement equity incentive plan grant commence february form employee stock option agreement equity incentive plan subsequent year grant form nonemployee director stock option agreement equity incentive plan grant prior form nonemployee director option agreement equity incentive plan initial grant form nonemployee director option agreement equity incentive plan annual grant form nonemployee director option agreement equity incentive plan annual grant commencing form restrict stock unit issuance agreement equity incentive plan annual grant nonemployee director commence form restrict stock award agreement equity incentive plan annual grant certain nonemployee director form performance share award agreement equity incentive plan grant table content exhibit exhibit footnote number description document form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan form restrict stock unit issuance agreement equity incentive plan grant prior form restrict stock unit issuance agreement equity incentive plan grant commencing form restrict stock unit issuance agreement equity incentive plan servicebase vest executive officer commence november form restrict stock unit issuance agreement equity incentive plan gilead sciences inc employee stock purchase plan amend restate november gilead sciences inc international employee stock purchase plan adopt november gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan gilead sciences inc defer compensation plan amend restate october gilead sciences inc severance plan amend december gilead sciences inc corporate bonus plan amend restate gilead sciences inc code section bonus plan base salary name executive officer offer letter date april registrant robin washington form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company squibb son llc bristolmyers squibb gilead sciences llc date september commercialization agreement gilead sciences limited bristolmyers squibb company date december table content exhibit exhibit footnote number description document amendment agreement date october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega follow exhibit license agreement date december registrant iocb rega license agreement license agreement date october registrant iocb rega october license agreement license agreement date december registrant iocb rega december license agreement amendment agreement registrant iocbrega date december amend license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant date august amend october license agreement december license agreement development license agreement registrant hoffmannla roche ltd hoffmannla roche inc date september amendment supplement date november development licensing agreement registrant hoffmannla roche ltd hoffmanla roche inc date september second amendment date december development licensing agreement registrant hoffmannla roche ltd hoffmanla roche inc date september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july license agreement japan tobacco inc registrant date march amendment license agreement japan tobacco inc registrant date second amendment license agreement japan tobacco inc registrant date amendment license agreement japan tobacco inc registrant date july fourth amendment license agreement japan tobacco inc registrant date july license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor therapeutics inc syntex usa inc date march amendment license agreement registrant successor therapeutics inc syntex usa inc date july amendment license agreement registrant successor therapeutics inc syntex usa inc date november table content exhibit exhibit footnote number description document amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date june amendment license agreement registrant successor therapeutics inc roche palo alto llc successor interest merger syntex usa inc date december license collaboration agreement registrant gilead sciences limited tibotec pharmaceutical date july second amendment license collaboration agreement registrant gilead sciences limited tibotec pharmaceutical date july master clinical commercial supply agreement gilead world market limited registrant patheon inc date january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date december addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date february tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited ampac fine chemical llc date november restate amend toll manufacturing agreement gilead sciences limited registrant nycome gmbh altana pharma oranienburg gmbh date november emtricitabine manufacturing supply agreement gilead sciences limit evonik degussa gmbh know degussa date june amendment emtricitabine manufacture supply agreement gilead sciences limit evonik degussa gmbh know degussa date april purchase sale agreement escrow instruction electronics imaging inc registrant date october subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule rule securities exchange act amend certification chief financial officer require rule rule securities exchange act amend certification chief executive officer chief financial officer require rule rule section chapter title united states code usc table content exhibit exhibit footnote number description document follow material registrant annual report year end december format extensible business report language xbrl include consolidated balance sheet december consolidated statement income year end december iii consolidated statement stockholder equity year end december consolidate statement cash flow year end december note consolidated financial statement file exhibit registrant current report form file march incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant current report form file november incorporate reference file exhibit registrant current report form file incorporate reference file exhibit registrant current report form file november incorporate reference file exhibit registrant current report form file incorporate reference file exhibit registrant current report form file october incorporate reference file exhibit registrant current report form file october incorporate reference file exhibit registrant registration statement form file june incorporate reference file exhibit registrant current report form file april incorporate reference file exhibit registrant current report form file august incorporate reference file exhibit registrant current report form file april incorporate reference file exhibit registrant current report form file december incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant current report form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference table content file exhibit registrant current report form file incorporate reference file exhibit registrant current report form file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant current report form file december incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant registration statement form file december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference information include registrant current report form file february incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit triangle pharmaceutical inc quarterly report form file november incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant quarterly report form quarter end march incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit therapeutic inc registration statement form amend originally file april incorporate reference file exhibit therapeutic inc quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference table content file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form file august incorporate reference agreement plan merger merger agreement contain representation warranty registrant cougar merger sub inc cgi pharmaceuticals inc solely specific date representation warranty solely purpose merger agreement subject important qualification limitation agree registrant cougar merger sub inc cgi pharmaceuticals inc representation warranty accurate complete specify date subject standard materiality provide merger agreement purpose allocate risk registrant cougar merger sub inc cgi pharmaceuticals inc establish matter fact agreement plan merger arresto merger agreement contain representation warranty registrant arroyo merger sub inc arresto biosciences inc solely specific date representation warranty solely purpose arresto merger agreement subject important qualification limitation agree registrant arroyo merger sub inc arresto biosciences inc representation warranty accurate complete specify date subject standard materiality provide arresto merger agreement purpose allocate risk registrant arroyo merger sub inc arresto biosciences inc establish matter fact agreement plan merger calistoga merger agreement contain representation warranty registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc solely specific date representation warranty solely purpose calistoga merger agreement subject important qualification limitation agree registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc representation warranty accurate complete specify date subject standard materiality provide calistoga merger agreement purpose allocate risk registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc establish matter fact agreement plan merger pharmasset merger agreement contain representation warranty registrant merger sub pharmasset inc solely specific date representation warranty solely purpose pharmasset merger agreement subject important qualification limitation agree registrant merger sub pharmasset representation warranty accurate complete specify date subject standard materiality provide pharmasset merger agreement purpose allocate risk registrant merger sub pharmasset establish matter fact management contract compensatory plan arrangement certification accompanie relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date irrespective general incorporation language contain filing furnish herewith certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule securities exchange act amend table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp redwood city california february table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset longterm marketable security intangible asset noncurrent asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion convertible senior note net longterm obligation total current liability longterm defer revenue longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note table content gilead sciences inc consolidated statement income thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative total cost expense income operation interest income net interest expense income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholders equity thousand gilead stockholder equity common stock additional accumulate total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december distribution noncontrolle interest net income loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation assumption stock option connection acquisition repurchase common stock balance december contribution noncontrolle interest net income loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation purchase convertible note hedge sale warrant defer tax asset convertible note hedge equity portion convertible note net issuance cost repurchase common stock balance december distribution noncontrolle interest net income loss unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan stockbase compensation repurchase common stock balance december accompany note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense inprocess research development impairment excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition net cash acquire capital expenditure net cash provide investing activity financing activity proceed issuance senior note net issuance cost proceed issuance convertible note net issuance cost proceed sale warrant purchase convertible note hedge proceed credit facility repayment credit facility proceed issuance common stock repurchase common stock extinguishment longterm debt repayment longterm obligation excess tax benefit stockbase compensation contribution distribution noncontrolle interest net cash provide financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay income taxis pay accompany note table content gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate seek improve care patient suffer lifethreatening disease world gilead primary area focus include human immunodeficiency virus hivaid liver disease hepatitis virus hbv hepatitis virus hcv cardiovascularmetabolic respiratory condition headquarter foster city california operations north america europe asia pacific continue seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise atripla truvada viread emtriva compleraeviplera hepsera ambisome letairis ranexa cayston vistide addition sell distribute certain product corporate partner royaltypaye collaborative agreement example hoffmannla roche ltd hoffmannla roche inc roche market tamiflu glaxosmithkline inc gsk market hepsera viread certain territory outside united states gsk market volibris outside united states astellas pharma inc markets ambisome united states canada astellas llc market lexiscan injection united states rapidscan pharma solutions inc market rapiscan certain territory outside united states menarini international operation luxembourg markets ranexa certain territory outside united states japan tobacco inc japan tobacco market truvada viread emtriva japan basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristol myers squibb company bms primary beneficiary record noncontrolle interest consolidated financial statement reflect bmss interest joint venture intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition applicable reporting period significant accounting policy estimate judgment preparation consolidate financial statement conformity gaap require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include critical accounting policy estimate related revenue recognition intangible asset allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate table content gilead sciences inc note consolidated financial statementscontinue revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue government rebate consolidated balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month prior expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue sale lexiscan ambisome astella llc astella pharma inc respectively recognize month follow month correspond sale occur royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur table content gilead sciences inc note consolidated financial statementscontinue contract revenue revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement income research development expense major component research development expense consist personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facility relate cost charge cost include clinical study cost expense incur clinical study cost significant component expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option restrict stock unit performance share assume exercise warrant relate convertible senior note table content gilead sciences inc note consolidated financial statementscontinue note note note note collectively convertible note determine treasury stock method principal convertible note settle cash conversion spread relate convertible note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread convertible note dilutive effect average market price common stock period exceed conversion price note note note note respectively note mature result consider impact period outstanding net income share calculation august warrant relate note expire result consider impact period outstanding net income share calculation average market price common stock exceed conversion price note dilutive effect include accompany table average market price common stock exceed conversion price note note note dilutive effect net income share period warrant relate note note note note dilutive effect average market price common stock period exceed warrant exercise price respectively average market price common stock exceed warrant exercise price relate convertible note warrant dilutive effect net income share period stock option purchase approximately million million million weightedaverage share common stock outstanding respectively include computation dilute net income share attributable gilead common stockholder effect antidilutive follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder thousand year end december numerator net income attributable gilead denominator weightedaverage share common stock outstanding calculation basic net income share attributable gilead common stockholder effect dilutive security stock option equivalent conversion spread relate note conversion spread relate note weightedaverage share common stock outstanding calculation dilute net income share attributable gilead common stockholder table content gilead sciences inc note consolidated financial statementscontinue stockbased compensation sharebase payment employee director recognize consolidated statement income base fair value benefit tax deduction excess recognize compensation cost report consolidated statement cash flow financing activity calculate pool excess tax benefit record additional paidin capital apic cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthan temporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content gilead sciences inc note consolidated financial statementscontinue subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable southern europe specifically greece italy portugal spain total approximately billion million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government rebate program cash discount prompt payment doubtful account sale return estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize prepay royalty prepay royalty capitalize cost initially equivalent present value future royalty obligation expect pay licensor expect future level product sale incorporate related technology review periodically expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review prepay royalty primarily comprise emtricitabine royalty pay emory university emory hiv indication royalty pharma purchase royalty interest own emory term transaction royalty pharma pay respectively total purchase price million emory exchange elimination emtricitabine royalty table content gilead sciences inc note consolidated financial statementscontinue emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million december unamortized prepay royalty asset million million respectively million million million amortize cost good sell respectively property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost million million consolidated balance sheet december respectively leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful life test goodwill indefinitelive intangible asset impairment annual basis annual test aware event occur change circumstance indicate reduction fair value asset carry amount intangible asset relate iprd project consider indefinitelive completion abandonment associate effort period asset consider indefinitelive amortize test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value iprd project respective carrying amount development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time intangible asset finite useful life primarily relate purchase market product acquisition therapeutics inc therapeutic amortize estimate useful life intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable amortize intangible asset relate ranexa table content gilead sciences inc note consolidated financial statementscontinue acquire therapeutic estimate useful life cost good sell amortization rate derive forecast future product sale ranexa product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast prospectively update rate amortize intangible asset relate ranexa increase future cost good sell record amortization expense amortize intangible asset relate lexiscan acquire therapeutic estimate useful life cost good sell straightline basis give current lexiscan revenue consist royalty receive collaboration partner lack ongoing access visibility partner future sale forecast reasonable estimate amortization rate forecasted product sale approach impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income record accumulate comprehensive income loss separate component stockholder equity net foreign currency exchange transaction gain loss include interest income net consolidated statement income net transaction loss total million million million respectively hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition limit risk counterpartie contract unable perform limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary table content gilead sciences inc note consolidated financial statementscontinue fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange forward option contract account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet carry value fair value convertible note billion billion respectively december carry value fair value convertible note billion billion respectively december march issue senior unsecured note april april note register offering aggregate principal billion carrying value fair value april note million billion respectively december december issue senior unsecured note december december note december december note december december note december december note aggregate principal billion carrying value fair value note billion billion respectively december fair value convertible note senior unsecured note base quote market value remain financial instrument report consolidated balance sheet amount approximate current fair value income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nontax deductible pharmaceutical excise tax require pay result enactment healthcare reform legislation account stock option sharebase payment merger acquisition future level spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period recent accounting pronouncement financial accounting standard board fasb issue amendment exist standard fair value measurement achieve common guidance generally accept accounting principle table content gilead sciences inc note consolidated financial statementscontinue international financial reporting standard addition amend standard revise certain requirement measure fair value disclosure fair value measurement require additional fair value measurement intend establish valuation standard affect valuation practice outside financial reporting update standard effective begin quarter adoption amendment material impact consolidate financial statement june fasb issue update exist standard comprehensive income presentation item comprehensive income oci prominent update standard prohibit current presentation oci statement stockholder equity instead provide public company option present oci continuous statement comprehensive income separate consecutive statement additionally update require reclassification adjustment display face financial statement oci report december fasb issue update indefinitely defer specific requirement presenting reclassification adjustment oci net income oci face financial statement deferral period exist requirement presentation reclassification adjustment continue follow update standard effective begin quarter adoption update standard impact presentation consolidate financial statement impact financial position result operation september fasb issue new accounting guidance intend simplify goodwill impairment testing entity allow perform qualitative assessment goodwill impairment determine quantitative assessment necessary guidance effective goodwill impairment test perform interim annual period fiscal year begin december standard effective begin quarter adoption guidance material impact consolidate financial statement december fasb issue new standard address disclosure requirement offset financial derivative instrument relate arrangement enable user financial statement understand effect arrangement company financial position update require company disclose net gross amount relevant asset liability offset note financial statement update standard effective begin quarter apply retrospectively comparative period present believe adoption standard material impact consolidate financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability review trading activity pricing investment measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum table content gilead sciences inc note consolidated financial statementscontinue level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation follow table summarize asset liability record fair value respective fair value classification level input fair value hierarchy define thousand december december level level level total level level level total asset debt security treasury security money market fund certificate deposit government agency fdic guarantee security municipal debt security nonus government security corporate debt security residential mortgage assetbacked security student loanbacke security total debt security equity security derivative liabilitie contingent consideration derivative follow table provide rollforward asset measure level input thousand year end december balance beginning period total realize unrealized gain loss include interest income net comprehensive income loss net sale marketable security transfer level balance end period table content gilead sciences inc note consolidated financial statementscontinue policy recognize transfer level classification actual date event change circumstance cause transfer asset measure fair value level input comprise auction rate security greek governmentissue bond availableforsale investment portfolio underlie asset auction rate security consist student loan auction rate security typically measure level input failure auction lack market activity liquidity experience begin require security measure level input fair value auction rate security determine discount cash flow model consider project cash flow issue trust underlie collateral expect yield project cash flow estimate base underlying loan principal bond outstanding payout formula weightedaverage life cash flow project consider collateral composition security relate historical project prepayment underlie student loan weightedaverage expect life seven year discount rate discount cash flow model base market condition comparable similar term assetbacke fix income security adjust illiquidity discount result annual discount rate auction rate security reset seven day maturity date range annual interest rate range december auction rate security continue earn interest continue fail auction lack market activity liquidity believe otherthantemporary impairment security december intend sell security likely require sell security recovery amortize cost basis greek government agree settle majority age outstanding account receivable zerocoupon bond expect trade discount face value december receive total million bond million receive year end december include transfer level estimate fair value greek zerocoupon bond level input current lack market activity liquidity discount rate fair value model bond base credit default swap rate ability intent hold bond maturity believe otherthantemporary impairment investment december december auction rate security record longterm marketable security consolidate balance sheet december greek governmentissue bond record shortterm longterm marketable security consolidate balance sheet contingent consideration liability measure fair value level input increase million december million december result acquisition arresto bioscience inc arresto january calistoga pharmaceuticals inc calistoga april estimate fair value contingent consideration liability acquisition base present value total earnout give consideration probability technical regulatory success achieve milestone event expect date evaluate change fair value contingent consideration liability end period note description acquisition table content gilead sciences inc note consolidated financial statementscontinue availableforsale security follow table summary availableforsale debt equity security record cash cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security generally base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december debt securitie treasury security money market fund certificate deposit government agency fdic guarantee security municipal debt security nonus government security corporate debt security residential mortgage assetbacked security student loanbacke security total debt security equity security total december debt security treasury security money market fund certificate deposit government agency fdic guarantee security municipal debt security nonus government security corporate debt security residential mortgage assetbacked security student loanbacke security total debt security equity security total follow table summarize classification availableforsale debt equity security consolidate balance sheet thousand december december cash cash equivalent shortterm marketable security longterm marketable security total table content gilead sciences inc note consolidated financial statementscontinue follow table summarize portfolio availableforsale debt security contractual maturity thousand december december amortize cost fair value amortize cost fair value year great year year great year year great year total follow table summarize gross realize gain loss relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale cost security sell determine base specific identification method table content gilead sciences inc note consolidated financial statementscontinue follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair thousand month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security treasury security government agency fdic guarantee security municipal debt security nonus government security corporate debt security certificate deposit residential mortgage assetbacke security student loanbacke security total december debt security treasury security certificate deposit government agency fdic guarantee security municipal debt security nonus government security corporate debt security residential mortgage assetbacked security student loanbacke security total december approximately respectively total number security unrealize loss position gross unrealized loss greek governmentissue bond reflect high discount rate valuation security compare imply interest rate security result primarily lack market activity liquidity underlie security gross unrealized loss auction rate security reflect high discount rate valuation security base review security believe otherthantemporary impairment security december intend sell security likely require sell security recovery amortize cost basis table content gilead sciences inc note consolidated financial statementscontinue derivative financial instrument operate foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition limit risk counterpartie contract unable perform limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability foreign subsidiary denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record interest income net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge interest income net effective component hedge record unrealized gain loss hedge instrument accumulate oci stockholder equity hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december reclassify product sale month notional amount foreign currency exchange contract outstanding billion billion december respectively table content gilead sciences inc note consolidated financial statementscontinue follow table summarize information fair value derivative instrument consolidate balance sheet thousand december asset derivative liability derivative fair classification value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract noncurrent asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivatives classification fair value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract noncurrent asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative table content gilead sciences inc note consolidated financial statementscontinue follow table summarize effect foreign currency exchange contract consolidate statement income thousands year end december derivative designate hedge net gain recognize oci effective portion net gain loss reclassify accumulated oci product sale effective portion net gain loss recognize interest income net ineffective portion amount exclude effectiveness testing derivative designate hedge net gain recognize interest income net material amount record interest income net year end december result discontinuance cash flow hedge acquisition calistoga pharmaceuticals inc february enter agreement acquire calistoga million plus potential payment million base achievement certain milestone transaction close april time calistoga whollyowne subsidiary calistoga privatelyheld biotechnology company base seattle washington focus development medicine treat cancer inflammatory disease acquisition provide portfolio proprietary compound selectively target isoform phosphoinositide kinase pik lead product candidate firstinclass specific inhibitor pik delta isoform pik delta preferentially express leukocyte involve variety inflammatory autoimmune disease hematological cancer acquisition account business combination calistogas result operation april include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire calistoga million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume april thousand iprd goodwill net liability assume total consideration transfer table content gilead sciences inc note consolidated financial statementscontinue iprd intangible asset associate iprd project relate product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate consider estimate weightedaverage cost capital company profile substantially similar calistoga acquirer estimate weightedaverage cost capital believe appropriate give unique characteristic acquisition include competitive bidding process rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result calistoga acquisition management believe goodwill mainly represent synergy expect combine research development operation acquire calistogas assemble workforce intangible asset qualify separate recognition consider calistoga acquisition material business combination disclose pro forma result operation require material business combination arresto biosciences inc december enter agreement acquire arresto million plus potential future payment base achievement certain sale target transaction close january time arresto whollyowne subsidiary arresto privatelyheld developmentstage biotechnology company base palo alto california focus develop antibody potential treatment fibrotic disease cancer lead product acquisition arresto humanize monoclonal antibody mab target human lysyl oxidaselike loxl protein addition ongoing phase study patient advance solid tumor time acquisition phase study initiate evaluate patient idiopathic pulmonary fibrosis acquisition account business combination arresto result operation january include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire arresto million consist cash pay prior closing million contingent consideration million table content gilead sciences inc note consolidated financial statementscontinue follow table summarize fair value asset acquire liability assume january thousand iprd goodwill defer tax asset defer tax liability net liability assume total consideration transfer iprd intangible asset associate iprd project relate product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate base estimate weightedaverage cost capital company profile substantially similar arresto comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result arresto acquisition management believe goodwill mainly represent synergy expect combine research development operation acquire arresto assemble workforce intangible asset qualify separate recognition consider arresto acquisition material business combination disclose pro forma result operation require material business combination cgi pharmaceuticals inc june enter agreement acquire cgi pharmaceuticals inc cgi million cash consist million upfront payment million contingent consideration payable base achievement clinical development milestone transaction close july time cgi whollyowne subsidiary cgi privatelyheld development stage pharmaceutical company base branford connecticut primarily focus small molecule chemistry protein kinase biology lead preclinical compound cgis library proprietary small molecule kinase inhibitor target spleen tyrosine kinase syk unique application treatment inflammatory disease include rheumatoid arthritis table content gilead sciences inc note consolidated financial statementscontinue cgi acquisition account business combination result operation cgi july include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire cgi million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume july thousands iprd goodwill defer tax asset defer tax liability net liability assume total consideration transfer iprd intangible asset associate iprd project relate preclinical syk product candidate management estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate base estimate weightedaverage cost capital company profile substantially similar cgi comparable estimate internal rate return cgis operation represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate effort fourth quarter record million impairment charge expense relate syk iprd asset acquire cgi impairment charge result change anticipate market share relate syk compound goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result cgi acquisition management believe goodwill mainly represent synergy expect combine research development operation acquire cgis assemble workforce intangible asset qualify separate recognition therapeutics inc april acquire therapeutic cash tender offer term agreement plan merger enter march therapeutic publiclyheld table content gilead sciences inc note consolidated financial statementscontinue biopharmaceutical company base palo alto california primarily focus discovery development commercialization small molecule drug treatment cardiovascular metabolic pulmonary disease therapeutic market product ranexa treatment chronic angina lexiscan injection use pharmacologic stress agent radionuclide mpi patient unable undergo adequate exercise stress therapeutic product candidate clinical development treatment cardiovascular metabolic pulmonary disease therapeutic acquisition account business combination result operation therapeutic april include consolidated statement income acquisition date determine april date acquire approximately outstanding share common stock therapeutic obtain effective control company acquisition complete day later april time therapeutic whollyowne subsidiary aggregate consideration transfer acquire therapeutic billion consist cash pay common stock equity instrument prior close billion fair value vest stock option assume million accordance merger agreement number gilead stock option restrict stock unit assume therapeutic stock option restrict stock unit convert determine base option conversion ratio conversion ratio calculate taking share acquisition price divide average closing price common stock consecutive trading day immediately precede include closing date april share fair value stock option assume calculate blackschole valuation model follow assumption market price share closing price common stock acquisition date expect term range year riskfree interest rate range expect volatility range dividend yield fair value restrict stock unit assume calculated acquisitiondate closing price share common stock include fair value vest stock option assume million consideration transfer acquisition assume vested restrict stock unit estimate fair value unvested stock option restrict stock unit assume million include consideration transfer recognize stockbased compensation expense remain future vest period award table content gilead sciences inc note consolidated financial statementscontinue follow table summarize asset acquire liability assume april thousand intangible assetsmarketed product intangible assetsiprd goodwill defer tax asset defer tax liability assetsliabilitie cash cash equivalent marketable security account receivable inventory prepaid current asset property plant equipment asset account payable accrue current liability convertible senior note liability total net liability total consideration transfer intangible asset substantial portion asset acquire consist intangible asset relate therapeutic market product ranexa lexiscan therapeutics iprd project management determine estimate acquisitiondate fair value intangible asset relate market product iprd project million million respectively million intangible asset relate market product million relate ranexa million relate lexiscan determine intangible asset finite useful life amortize respective useful life estimate period associate product patent expire period intangible asset expect contribute future cash flow related product amortize intangible asset relate ranexa estimate useful life amortization rate derive forecast future product sale ranexa amortize intangible asset relate lexiscan estimate useful life straightline basis give current lexiscan revenue consist royalty receive collaboration partner lack ongoing access visibility partner future sale forecast reasonable estimate amortization rate forecasted product sale approach weightedaverage amortization period intangible asset approximately year million intangible asset relate iprd project million relate product candidate phase clinical study treatment diabetes hypertriglyceridemia remain balance intangible asset relate iprd project represent inprocess project single project comprise significant portion total value intangible asset relate iprd project consider indefinitelive completion abandonment associate effort period asset consider indefinitelive amortize table content gilead sciences inc note consolidated financial statementscontinue tested impairment annual basis annual test aware event occur change circumstance indicate reduction fair value iprd project respective carrying amount fourth quarter record million impairment charge relate certain iprd asset acquire therapeutic future plan develop deem future use market participant charge relate adentri tecadenoson program record expense majority impairment charge relate program terminate fourth quarter unfavorable result pharmacokinetic pharmacodynamic test demonstrate limited effectiveness compound patient give result believe alternative future use market participant quarter million purchase iprd project therapeutic complete reclassify finite live intangible asset currently amortize estimate useful life december million iprd asset acquire therapeutic remain consolidated balance sheet defer tax asset defer tax liability million defer tax asset result acquisition primarily related federal state net operating loss tax credit carryforward million defer tax liability result acquisition primarily relate difference book basis tax basis intangible asset relate market product iprd project conclude likely realize benefit defer tax asset relate certain state net operating loss carryforward result valuation allowance million record related defer tax asset presentation purpose million defer tax liability noncurrent nature net noncurrent defer tax asset consolidate balance sheet result impairment charge record fourth quarter reduce defer tax liability relate iprd project million convertible senior note result acquisition assume convertible note therapeutic consist senior subordinate convertible note senior subordinated convertible note senior subordinated convertible debenture convertible note recognize fair value acquisition date offer repurchase convertible note consideration par value plus accrue interest require term respective convertible note agreement follow occurrence change control fundamental change define agreement december convertible note extinguish goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result acquisition management believe goodwill mainly represent synergies economy scale expect combine operation therapeutic goodwill expect deductible income tax purpose record goodwill intangible asset consolidated balance sheet acquisition date goodwill test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry table content gilead sciences inc note consolidated financial statementscontinue restructure second quarter implement plan close research operation durham north carolina consolidate liver disease research activity foster city california restructuring plan include consolidation liver disease organization exit certain facility record total million million sga expense expense respectively relate employee severance facility relate expense plan december close operation durham incur expect incur additional significant cost connection plan second quarter approve plan realize certain synergy result therapeutics acquisition realign cardiovascular operation eliminate redundancy restructuring plan include consolidation realignment cardiovascular organization exit certain facility termination certain contractual obligation record facilitiesrelate expense million sga expense comparatively record million million restructuring expense sga expense respectively record million million sga expense respectively expense primarily relate employee severance relocation lease termination cost facilitiesrelate expense total cost incur plan million million sga expense respectively incur expect incur additional cost connection plan follow table summarize restructure liability accrue change amount period restructuring plan relate cardiovascular operation thousand employee severance termination facility benefit relate cost balance december cost incur period cost pay settle period balance december cost incur period cost pay settle period balance december cost incur period cost pay settle period balance december inventory inventory summarize follow thousand december raw material work process finish good total table content gilead sciences inc note consolidated financial statementscontinue december joint venture form gilead bms note include consolidated financial statement hold million million inventory respectively efavirenz active pharmaceutical ingredient purchase bms bmss estimate net sell price efavirenz property plant equipment property plant equipment summarize follow thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total september complete purchase clinical biologic manufacturing facility certain process development asset locate oceanside california pay total purchase price million cash include transaction cost account transaction asset acquisition purchase price allocate base fair value acquire tangible asset consist primarily property plant equipment intangible asset follow table summarize carry intangible asset thousand december goodwill finitelive intangible asset indefinitelive intangible asset total table content gilead sciences inc note consolidated financial statementscontinue goodwill follow table summarize change carry goodwill thousand balance december goodwill result acquisition arresto goodwill result acquisition calistoga balance december finitelive intangible asset follow table summarize finitelive intangible asset thousand december december gross carry accumulate gross carry accumulate amortization amortization intangible asset ranexa intangible asset lexiscan total amortization expense relate intangible asset million million year end december respectively record cost good sell consolidated statement income amortization expense relate intangible asset million year end december record primarily cost good sell consolidated statement income weightedaverage amortization period intangible asset approximately year december estimate future amortization expense associate intangible asset succeed fiscal year follow thousands fiscal year total indefinitelive intangible asset december indefinitelive intangible asset million consist million million purchase iprd acquisition arresto calistoga respectively fourth quarter record million impairment charge relate certain iprd asset acquire cgi impairment charge result change anticipate market share relate syk compound million purchase iprd project therapeutic complete reclassify finitelived intangible asset currently amortize estimate useful life table content gilead sciences inc note consolidated financial statementscontinue december indefinitelive intangible asset million consist million million purchase iprd acquisition cgi therapeutic respectively fourth quarter record million impairment charge expense relate certain iprd asset acquire therapeutic future plan develop deem future use market participant majority impairment charge relate program product candidate phase clinical study treatment diabetes hypertriglyceridemia terminate unfavorable result pharmacokinetic pharmacodynamic test demonstrate limited effectiveness compound patient give result believe alternative future use market participant collaborative arrangement time time result enter strategic collaboration hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure base applicable guidance contractual term provide control entity require consolidate entity entity consolidated control mean majority voting interest refer variable interest entity vie assess primary beneficiary vie base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december determine certain investee company vie respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america enter collaboration arrangement bms united states develop commercialize singletablet regiman contain truvada bmss sustiva efavirenz sell atripla collaboration structure joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate ownership interest joint venture share product revenue cost reflect respective economic interest bms gilead base proportion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort level agree annually bms gilead second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party begin reduce joint promotional effort canada launch complera anticipation launch quad party continue collaborate activity manufacture regulatory compliance pharmacovigilance responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value joint venture receive approval fda sell atripla united states bms amend joint venture collaboration agreement allow joint venture sell atripla canada joint venture receive approval health canada sell atripla canada december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz market amount table content gilead sciences inc note consolidated financial statementscontinue include inventory consolidate balance sheet december total asset hold joint venture billion billion respectively consist primarily cash cash equivalent account receivable include intercompany receivables gilead inventory december total liability hold joint venture billion million respectively consist primarily account payable include intercompany payable gilead accrue expense asset liability amount reflect impact intercompany elimination include consolidated balance sheet primary beneficiary joint venture legal structure joint venture limit recourse creditor general credit asset europe gilead sciences limit whollyowne subsidiary ireland bms enter collaboration arrangement commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory copromote atripla bms start limited number activity jointly manage party long coordinate detail promotional activity region responsible accounting financial reporting tax reporting collaboration european commission approve atripla sale european union december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity share marketing sale effort bm major market country party agree provide equivalent sale force effort revenue cost sharing base relative ratio respective net selling price truvada efavirenz pari gmbh result acquisition corus pharma inc corus assume rights february development agreement corus pari gmbh pari development cayston development inhalation delivery device product term agreement obligate pay pari service render subject achievement specific milestone obligate pay certain milestone payment pari addition royalty payment base net sale cayston agreement provide right reduce royalty rate payable pari pay pari million reduce royalty rate agreement cayston approve commercialization time payment record payment expense consolidate statement income enter commercialization agreement pari provide supply manufacture inhalation delivery device accessory use cayston term agreement obligate pay royalty future net sale product pursuant development agreement table content gilead sciences inc note consolidated financial statementscontinue receive marketing approval fda cayston treatment improve respiratory symptom cystic fibrosis patient aeruginosa cayston conditionally approve europe canada receive approval roche enter development license agreement agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year million worldwide net sale calendar year worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement record total million million million tamiflu royalty respectively result acquisition therapeutic assume right agreement therapeutic roche exclusive worldwide license ranexa license agreement pay initial license fee obligate certain payment roche receipt second product approval ranexa follow major market country france germany italy united states united kingdom receive fda approval ranexa treatment chronic angina pay million roche accordance agreement receive marketing authorization european medicine agency ema ranexa treatment chronic angina european union member state pay million roche relate approval capitalize noncurrent asset consolidated balance sheet amortize useful patent life approximately year expiring enter amendment agreement roche relate ranexa amendment provide exclusive worldwide commercial right ranexa potential indication human term amendment upfront payment roche obligate royalty payment roche worldwide net product sale license product addition obligate additional milestone payment achievement certain regulatory approval table content gilead sciences inc note consolidated financial statementscontinue japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv infection bear cost expense associate commercialization effort term agreement incur upfront license fee million include expense future alternative use technology record million expense relate milestone incur result dose patient phase clinical study record million expense relate milestone pay related dose patient phase clinical study october submit nda fda marketing approval oncedaily singletablet quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine december fda accept nda review fda set target review date quad august prescription drug user fee act december announce submit marketing authorization application ema marketing approval singletablet regiman record million expense december relate milestone incur connection filing obligate additional payment achievement milestone pay royalty future product sale arise collaboration glaxosmithkline inc grant gsk right commercialize hepsera oral antiviral treatment chronic hbv asia latin america certain territory agreement retain right hepsera united states canada europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hbv territory significant include china japan south korea taiwan gsk responsibility development commercialization hepsera territory term agreement receive upfront license payment million receive aggregate million milestone payment relate commercial approval hepsera country receive aggregate million milestone payment gsk achievement gsk consecutive quarter hepsera gross sale exceed million achievement certain drug status china upfront license fee milestone payment record defer revenue total million million amortize contract revenue respectively terminate supply agreement gsk allow gsk assume manufacture supply obligation hepsera use gsk territory result termination supply agreement recognize remain million balance defer revenue contract revenue term agreement gsk require pay royalty net sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory record million million million royalty revenue respectively enter agreement gsk commercialize viread treatment chronic hbv country asia agreement retain exclusive right commercialization viread chronic hbv hong kong singapore south korea taiwan china gsk exclusive commercialization right viread chronic hbv company pay royalty sale viread chronic hbv respective asian territory table content gilead sciences inc note consolidated financial statementscontinue grant gsk exclusive right commercialize tenofovir disoproxil fumarate chronic hbv japan gsk require pay royalty sale tenofovir disoproxil fumarate chronic hbv territory result acquisition myogen inc myogen assume right march license distribution supply agreement myogen gsk term license agreement gsk exclusive right market ambrisentan active pharmaceutical ingredient letairis volibris pulmonary arterial hypertension territory outside united states receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development significant milestone payment receive date include milestone payment million gsk validation ema marketing authorization application volibris million milestone payment relate european commission marketing authorization approval volibris receive million milestone payment achievement gsk consecutive quarter volibris net sale exceed million milestone upfront license payment record defer revenue recognize contract revenue remain period performance obligation agreement approximately year recognize million million million contract revenue respectively astella llc astella pharma inc astellas applicable result acquisition therapeutic assume right july collaboration agreement therapeutic astella llc develop market second generation pharmacologic mpi stress agent agreement astella receive exclusive north american right lexiscan backup compound receive fda approval lexiscan use pharmacologic stress agent mpi study patient unable undergo adequate exercise stress term agreement product market astella launch united states recognize million million million royalty revenue respectively astella relate sale lexiscan agreement astella pharma inc relate right market ambisome term agreement astella responsible promotion ambisome united states canada exclusive marketing right ambisome rest world subject obligation pay royalty astellas connection sale significant market asia receive royalty astellas sale ambisome unites states canada connection agreement record royalty revenue million million million respectively tibotec pharmaceutical enter license collaboration agreement tibotec pharmaceutical tibotec whollyowne subsidiary johnson johnson develop commercialize fixeddose combination table content gilead sciences inc note consolidated financial statementscontinue truvada tibotecs nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell trade complera united states eviplera european union license collaboration agreement tibotec grant exclusive license compleraeviplera administration adult oncedaily oral dosage form worldwide exclude certain middle income develop world country japan party restrict combine drug product drug accordance term agreement reimburse million approximately million development cost incur tibotec rilpivirine december record million approximately million million approximately million million approximately million respectively reimbursable expense incur tibotec development rilpivirine responsible manufacturing compleraeviplera lead role registration distribution commercialization combination product license country tibotec exercise right codetail combination product country gilead sell party price combination product expect sum price truvada rilpivirine component cost rilpivirine purchase tibotec combination product approximate market price rilpivirine specified percentage thirty percent amend agreement include distribution compleraeviplera rest world distribute product north america europe latin america australia new zealand tibotec distribute product region include japan russia longterm obligation financing arrangement follow table summarize carry borrowing financing arrangement thousand december convertible senior note convertible senior note convertible senior note convertible senior note december senior unsecured note december senior unsecured note april senior unsecured note december senior unsecured note december senior unsecured note total debt net current portion convertible senior note total longterm debt net convertible senior note april issue million note million note private placement pursuant rule securities act amend table content gilead sciences inc note consolidated financial statementscontinue note mature repay aggregate principal balance million pay million cash relate conversion spread note represent conversion value excess principal receive million cash convertible note hedge relate note warrant relate note expire august note note issue par bear interest rate respectively debt issuance cost million record noncurrent asset amortize interest expense contractual term note note initial conversion rate note share principal note represent initial conversion price approximately share initial conversion rate note share principal note represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note note convert subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note conversion value note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal note note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note exceed principal note million concurrent issuance note note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidate balance sheet convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note note note remain outstanding conversion million share common stock underlie warrant subject table content gilead sciences inc note consolidated financial statementscontinue customary antidilution adjustment warrant strike price share warrant expire share warrant expire exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price contemporaneously close sale note note portion net proceed note issuance proceed warrant transaction repurchase million share common stock million current accounting guidance bifurcated conversion option note note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note note follow table summarize information equity liability component note note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note convertible senior note total convertible senior note year end december recognize million million million respectively interest expense relate contractual coupon rate amortization debt discount note note effective interest rate liability component note note respectively convertible senior note july issue billion note billion note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost primarily comprise million banker fee majority record noncurrent asset amortize interest expense contractual term note note aggregate principal note note sell reflect exercise initial purchaser option purchase additional note cover overallotment initial conversion rate note share principal represent initial conversion price approximately share initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note note convert prior april april respectively follow circumstance calendar quarter commencing table content gilead sciences inc note consolidated financial statementscontinue september closing price common stock trading day consecutive period consecutive trading day end trading day precede calendar quarter great applicable conversion price applicable trading day business day period measurement period consecutive trading day trading day period trading price principal note product report sale price common stock applicable conversion rate trading day occurrence specify corporate transaction distribution certain stock right cash amount asset shareholder occurrence change control april case note april case note holder convert note time regardless forego circumstance generally conversion holder receive cash equal less principal note conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal note note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note note exceed principal amount note concurrent issuance note note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidate balance sheet convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share warrant expire share warrant expire exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price net proceed issuance convertible note repurchase share common stock repay exist indebtedness table content gilead sciences inc note consolidated financial statementscontinue current accounting guidance bifurcated conversion option note note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note note follow table summarize information equity liability component note note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note convertible senior note total convertible senior note year end december recognize million million respectively interest expense relate contractual coupon rate amortization debt discount note note effective interest rate liability component note note respectively april senior unsecured note march issue april note register offering aggregate principal billion april note mature april pay interest fix annual rate debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term april note april note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point plus case accrue unpaid interest note redeem date redemption time january redeem note principal note redeem plus accrue unpaid interest date redemption addition event occurrence change control downgrade rating april note investment grade rating standard poor rating service moodys investors service inc holder require purchase portion note price equal principal plus accrue unpaid interest net proceed general corporate purpose include repayment exist indebtedness repurchase common stock december senior unsecured note december issue december note december note december note december note register offer million million billion billion respectively aggregate principal billion note mature december table content gilead sciences inc note consolidated financial statementscontinue pay interest fix annual rate respectively debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case december note december note basis point case december note december notes plus case accrue unpaid interest note redeem date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating series note investment grade rating standard poor rating service moodys investors service inc holder series note require purchase portion note series price equal aggregate principal note repurchase plus accrue unpaid interest plan use net proceed fund acquisition pharmasset inc pharmasset announce november complete january note credit facility amend restate credit agreement whollyowne subsidiary gilead biopharmaceutics ireland corporation borrow aggregate billion revolving credit loan credit agreement include subfacility swingline loan letter credit loan credit agreement bear interest interest rate libor plus margin range basis point basis point base rate describe credit agreement reduce commitment prepay loan credit agreement time penalty subject certain condition credit agreement terminate december unpaid borrowing thereunder shall payable time april connection acquisition therapeutic borrow million credit agreement partially fund acquisition december repay million credit agreement borrow million credit agreement fund stock repurchase august repay million borrow credit agreement proceed convertible senior note issue july december million letter credit outstanding billion credit agreement require comply certain covenant credit agreement december compliance covenant subsequently january fully repay outstanding obligation terminate credit agreement table content gilead sciences inc note consolidated financial statementscontinue commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city fremont palo alto san dimas california branford connecticut princeton new jersey seattle washington dublin cork areas ireland london area united kingdom operate lease sale marketing administrative facilities europe canada asia pacific lease expire date lease contain option renew certain facility lease contain rent escalation clause significant lease relate facility seattle washington expire year term lease provide consecutive right extend term lease contain annual percent rent escalation clause lease require pay additional amount operating expense maintenance lease corporate aircraft vary term renewal option expiration lease term lease expense operating lease approximately million million million year end december respectively aggregate noncancelable future minimum rental payment operating lease follow thousand legal proceeding june receive subpoena united states attorney office northern district california request document relate manufacture relate quality distribution practice atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range loss determine give early stage inquiry party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately million million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion million billion year end december respectively table content gilead sciences inc note consolidated financial statementscontinue stockholder equity stock repurchase program repurchase retire million share common stock average purchase price share aggregate purchase price million open market transaction billion stock repurchase program approve board october receive million share common stock accelerate share repurchase agreement complete march december complete stock repurchase october stock repurchase program january board authorize program repurchase common stock billion open market private block transaction pursuant rule plan privately negotiate purchase mean complete plan time board authorize threeyear billion stock repurchase program december repurchase billion common stock program remain authorize stock repurchase program billion spend total billion repurchase retire million share common stock average purchase price share january board authorize threeyear billion stock repurchase program initiate purchase program september completion stock repurchase program december repurchase million common stock january stock repurchase program remain authorize stock repurchase plan billion spend total billion repurchase retire million share common stock average purchase price share use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning result stock repurchase reduce common stock apic aggregate million charge million retain earning result stock repurchase reduce common stock apic aggregate million charge billion retain earning result stock repurchase reduce common stock apic aggregate million charge billion retain earning prefer stock share authorize preferred stock issuable series board authorize determine designation power preference right series designate share series junior participate prefer stock potential issuance november right agreement computershare limit amend right plan prefer stock outstanding december right plan right plan provide distribution prefer stock purchase right dividend share common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase common stock discount market price time payment specify exercise price purchase right addition event table content gilead sciences inc note consolidated financial statementscontinue certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade common stock october october board approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october amendment clarify amendment enter connection increase designate number share series junior participate prefer stock potential issuance right plan equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan plan replace exist equity plan prior plan remain share available future grant prior plan transfer plan additionally award grant prior plan expire terminate exercised share common stock reserve award add pool available share common stock plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issue maximum share fullvalue award restrict stock restrict stock unit performance share performance unit extend settle common stock phantom share term plan plan authorize issuance total share common stock december share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share connection acquisition therapeutic assume therapeutics equity incentive plan amend restate nonemployee director stock option plan amend restate equity incentive plan amend restate nonstatutory incentive plan amend restate employee commencement incentive plan amend restate collectively therapeutic plan majority option issue outstanding therapeutic plan april convert option purchase approximately million share common stock remain subject original term condition share available future grant therapeutic plan table content gilead sciences inc note consolidated financial statementscontinue connection acquisition arresto assume arresto equity incentive plan arresto plan option issue outstanding arresto plan convert option purchase common stock effective january number convert option purchase common stock significant share available future grant arresto plan follow table summarize activity stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand year end december weight weight weight average average average share exercise price share exercise price share exercise price outstanding beginning year grant assume forfeited expired exercise outstanding end year exercisable end year weightedaverage grant date fair value option grant year total intrinsic value option exercise year end december million million million respectively total fair value stock option vest year end december million million million respectively december number option outstanding expect vest net estimate future option forfeiture weight average exercise price share aggregate intrinsic value million weightedaverage remain contractual life year aggregate intrinsic value stock option outstanding stock option exercisable december million million respectively december weightedaverage remain contractual life option outstanding option exercisable year respectively december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performance award plan grant performancebase restricted stock unit vest achievement specify market performance goal relative predetermine peer group actual number common share ultimately issue calculated multiplying number performance unit payout percentage range performance awards vest committee subcommittee board determine achieve specified market performance goal january grant performancebase unit award performance share table content gilead sciences inc note consolidated financial statementscontinue performance share performance share respectively award vest single threeyear performance measurement vest period performance share awards fair value performance share grant estimate grant date monte carlo valuation methodology weightedaverage grant date fair value performance share share respectively recognize million million million stockbase compensation expense respectively relate performance share december million unrecognized compensation cost relate performance share expect recognize estimate weightedaverage period year grant performancebase restrict stock unit certain employee plan vest award subject achievement specify performance goal number award issue date significant restrict stock unit grant restrict stock unit rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest generally rsus vest ratably annual basis year date grant award grant prior start january rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information thousand share amount year end december weight weight weight average average average grant grant grant date date date fair value fair value fair value share share share share share share outstanding beginning year grant assume vested forfeited outstanding end year total fair value rsus vest year end december million million million respectively december million unrecognized compensation cost relate nonveste rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer twoyear lookback feature automatic reset feature provide table content gilead sciences inc note consolidated financial statementscontinue offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espps previously authorize available pool share share issue espp million total share common stock reserve issuance espp share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income thousands year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax year end december capitalize million million million stockbase compensation cost inventory respectively million million million remain inventory december respectively stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach unvested stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully table content gilead sciences inc note consolidated financial statementscontinue transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout comprehensive income loss comprehensive income loss comprise net income certain change stockholder equity exclude net income change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealized gain loss relate availableforsale security net tax impact respectively net unrealized gain loss relate cash flow hedge net tax impact respectively reclassification adjustment net tax impact respectively comprehensive income loss table content gilead sciences inc note consolidated financial statementscontinue balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized gain loss availableforsale security net unrealize gain cash flow hedge cumulative foreign currency translation adjustment accumulate comprehensive income segment information product sale operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment majority product similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december antiviral product atripla truvada viread hepsera compleraeviplera emtriva total antiviral product ambisome letairis ranexa product total product sale table content gilead sciences inc note consolidated financial statementscontinue follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner year end december united states outside united states france united kingdom spain italy germany switzerland european country country total revenue outside united states total revenue follow table summarize revenue customer individually account total revenue percentage total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment table content gilead sciences inc note consolidated financial statementscontinue income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income billion billion billion respectively cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately billion billion december respectively residual tax liability amount remit approximately billion billion december respectively difference provision income taxis compute apply federal statutory income tax rate income provision income taxis follow thousands year end december income provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation provision income taxis table content gilead sciences inc note consolidated financial statementscontinue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward capitalize intangible net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance decrease million year end december increase million million year end december respectively conclude base standard set forth fasb accounting standard codification relate income taxis likely realize benefit defer tax asset relate certain state net operating loss credit carryforward december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards table content gilead sciences inc note consolidated financial statementscontinue income tax return audit federal state foreign tax authority currently examination internal revenue service irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income december accrue interest penalty relate unrecognized tax benefit million million respectively december believe reasonably possible unrecognized tax benefit significantly change month expect clarification irs tax authority uncertain tax position follow rollforward total gross unrecognized tax benefit liability year end december thousand december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period defer compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match total matching contribution expense gilead plan year end december million million million respectively maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal table content gilead sciences inc note consolidated financial statementscontinue revenue code plan officer senior grade level employee contribute annual salary annual bonus director contribute annual retainer fee effective director defer rsu award amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date available plan receive defer compensation payment subsequent event acquisition pharmasset inc november enter definitive agreement acquire pharmasset billion cash tender offer subsequent merger transaction close january time pharmasset whollyowne subsidiary finance transaction approximately billion cash hand billion bank debt billion senior unsecured note issue december pharmasset clinicalstage pharmaceutical company locate princeton new jersey commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset research development effort focus nucleosidetide analogs class compound act alternative substrate viral polymerase inhibit viral replication believe acquisition provide opportunity complement exist hcv portfolio help advance effort develop alloral regimen treatment hcv pharmasset lead compound nucleotide analog hcvinfecte individual genotype know evaluate phase clinical study expect receive significant datum clinical trial evaluate february announce datum indicate ribavirin treatment genotype patient prior null response interferoncontaine regiman week sufficient cure disease currently conduct additional phase study hcv infected genotype patient include treatment nave patient result expect end quarter second quarter early quarter currently process value asset acquire liability assume business combination completion valuation analysis expect provide amount recognize acquisition date major class asset acquire liability assume bank debt january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement fiveyear revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition table content gilead sciences inc note consolidated financial statementscontinue loan fiveyear revolve credit agreement shortterm revolve credit agreement term loan credit agreement bear interest eurodollar rate plus applicable margin base rate plus applicable margin define applicable credit agreement reduce commitment prepay loan agreement time premium penalty fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility year revolve credit agreement terminate amount owe thereunder shall payable january shortterm revolve credit agreement terminate amount owe thereunder shall payable january request maturity date extend january principal repayment installment term loan credit agreement payable specify term loan credit agreement final principal installment payment payable january quarterly result operation unaudite follow amount thousand share amount quarter quarter quarter quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute fourth quarter record million impairment charge expense relate certain iprd asset acquire cgi note fourth quarter record million impairment charge expense relate certain iprd asset acquire therapeutic note table content gilead sciences inc schedule valuation qualifying account thousand balance addition balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition table content